

1                   **Antibody Response in Snakes with Boid Inclusion Body Disease**

2           Katharina Windbichler<sup>1</sup>, Eleni Michalopoulou<sup>2</sup>, Pia Palamides<sup>1</sup>, Theresa Pesch<sup>1</sup>, Christine  
3                   Jelinek<sup>1</sup>, Olli Vapalahti<sup>3,4</sup>, Anja Kipar<sup>1,3</sup>, Udo Hetzel<sup>1,3</sup>, Jussi Hepojoki<sup>1,4</sup>

<sup>1</sup>Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich,  
Switzerland

<sup>2</sup>Department of Veterinary Pathology and Public Health, Institute of Veterinary Science,  
University of Liverpool, Liverpool, UK

<sup>3</sup>University of Helsinki, Faculty of Veterinary Medicine, Department of Veterinary  
Biosciences, Helsinki, Finland

<sup>4</sup>University of Helsinki, Faculty of Medicine, Medicum, Department of Virology, Helsinki,  
Finland

Running title: Antibodies in BIBD

\* Corresponding author

Address for corres

***Present address:*** Pia's new address. Max von Pettenkofer-Institute, Ludwig-Maximilian  
University Munich, Munich, Germany

4                   ***Christines current address:*** Klinik für Vögel, Reptilien, Amphibien und  
5                   Fische, Justus-Liebig University Gießen, Gießen, Germany

Word number in abstract and importance: 243 and 144

Word number in text: 8975

6

## ABSTRACT

7 Boid Inclusion Body Disease (BIBD) is a potentially fatal disease reported in captive boid  
8 snakes worldwide that is caused by reptarenavirus infection. Although the detection of  
9 intracytoplasmic inclusion bodies (IB) in blood cells serves as the gold standard for the *ante*  
10 *mortem* diagnosis of BIBD, the mechanisms underlying IB formation and the pathogenesis of  
11 BIBD are unknown. Knowledge on the reptile immune system is sparse compared to the  
12 mammalian counterpart, and in particular the response towards reptarenavirus infection is  
13 practically unknown. Herein, we investigated a breeding collection of 70 *Boa constrictor*  
14 snakes for BIBD, reptarenavirus viraemia, anti-reptarenavirus IgM and IgY antibodies, and  
15 population parameters. Using NGS and RT-PCR on pooled blood samples of snakes with and  
16 without BIBD, we could identify three different reptarenavirus S segments in the collection.  
17 The examination of individual samples by RT-PCR indicated that the presence of University  
18 of Giessen virus (UGV)-like S segment strongly correlates with IB formation. We could also  
19 demonstrate a negative correlation between BIBD and the presence of anti-UGV NP IgY  
20 antibodies. Further evidence of an association between antibody response and BIBD is the  
21 finding that the level of anti-reptarenavirus antibodies measured by ELISA was lower in  
22 snakes with BIBD. Furthermore, female snakes had a significantly lower body weight when  
23 they had BIBD. Taken together our findings suggest that the detection of the UGV-/S6-like S  
24 segment and the presence of anti-reptarenavirus IgY antibodies might serve as a prognostic  
25 tool for predicting the development of BIBD.

26

## IMPORTANCE

27 Boid Inclusion Body Disease (BIBD) is a transmissible viral disease of captive snakes and  
28 causes severe losses in collections worldwide. BIBD is caused by reptarenavirus infection,  
29 which can persist over several years without overt signs. The pathogenesis of BIBD is largely  
30 unknown and anecdotal evidence links BIBD with the occurrence of bacterial infections and  
31 neoplasms, indicating potential immunosuppression. Herein we studied a collection of 70 boa  
32 constrictors for BIBD, reptarenavirus viraemia and antibodies against reptarenaviruses, and  
33 correlated the findings with other parameters. Our results show that University of Giessen  
34 virus-like S segment significantly associates with BIBD. They also suggest that the antibody  
35 response against reptarenaviruses among snakes with BIBD is at a lower level than in snakes  
36 without BIBD. While these findings indicate that the anti-reptarenavirus antibody response  
37 per cannot serve as a diagnostic tool for BIBD, they provide evidence supporting  
38 reptarenavirus infection-induced immunosuppression.

39

## INTRODUCTION

40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Boid inclusion body disease (BIBD) is a widespread disease of captive boid snakes known since the 1970s (1–3). The disease is characterised by the presence of eosinophilic and electron-dense intracytoplasmic inclusion bodies (IBs) in most cell types of affected snakes (1–3). In the early 2010s, we and others identified arenaviruses as the most likely causative agents of BIBD, by demonstrating that the IBs consist mainly of arenavirus nucleoprotein (4–7). The causative link was later confirmed by experimental infection of boas and pythons with reptarenavirus isolates (8). The family *Arenaviridae* in the order *Bunyvirales* currently comprises four genera: *Mammarenavirus*, *Reptarenavirus*, *Hartmanivirus*, and *Antennavirus* (9). The arenaviruses found in snakes with BIBD belong to the genera *Reptarenavirus* and *Hartmanivirus* (9).

The genome of reptarenaviruses is a bi-segmented single-stranded negative-sense RNA with ambisense coding strategy. The small (S) segment encodes the nucleoprotein (NP) and the glycoprotein precursor (GPC), while the matrix protein (ZP) and the RNA-dependent RNA polymerase (RdRp) are encoded by the large (L) segment (10). The genome of hartmaniviruses is similar, except that it lacks the ZP (10). Snakes with BIBD are commonly co-infected with several reptarenaviruses, and, curiously, they often harbour more L than S segments (1, 11, 12). The co-existence of multiple segments in an infected snake likely allows re-assortment of L and S segments (12). The genetic variation between the known reptarenaviruses is tremendous and up to now L segments of approximately 30 different reptarenavirus species are known (1, 10–12). The genetic dissimilarity significantly hampers the development of sensitive “pan-reptarenavirus” RT-PCR tools. Therefore, since the IBs occur in blood cells including erythrocytes, IB detection in blood smears represents the current gold standard for *ante mortem* BIBD diagnosis (3, 13). However, the presence of IBs does not associate with pathological changes or clinical signs, and thus snakes with reptarenavirus infection can remain clinically healthy for a long time (4, 8). Subclinical

66 infections together with horizontal and vertical transmission of reptarenaviruses (1, 12) are  
67 the likely reasons behind reptarenavirus co-infections being rather a rule than an exception in  
68 snakes with BIBD.

69 Despite the above facts, BIBD appears to be ultimately lethal (1–3). Clinical features  
70 observed in snakes with BIBD include neurological signs, regurgitation, anorexia, pneumonia,  
71 stomatitis, and lymphoproliferative disorders (2, 13, 14). The pathogenesis is poorly  
72 understood, however, the fact that bacterial infections and/or neoplastic processes are  
73 common in snakes with BIBD suggests that the disease is associated with immunosuppression  
74 (2–4). Lymphocytic choriomeningitis virus (LCMV), the prototype arenavirus (genus  
75 *Mammarenavirus*), induces immunosuppression by inhibition of type I interferon (IFN-I)  
76 production (15–17). The underlying mechanism is prevention of the RIG-I(retinoic acid  
77 inducible gene-I)/MAVS(mitochondrial antiviral signaling) pathway by the NP of LCMV (10,  
78 17). The IFN-I production is further inhibited by the ZP of LCMV, which enters the nucleus  
79 and induces re-localisation of promyelocytic leukemia (PML) bodies to the cytoplasm (10, 18,  
80 19). Intriguingly, PML bodies contribute to tumour suppression which is hampered by their  
81 cytoplasmic localisation (20), thus the ZP of reptarenaviruses could promote tumourigenesis  
82 by such a mechanism. Additionally, the ZP of New World arenaviruses prevents the type I  
83 IFN response by binding to RIG-I (17).

84 Currently, not much is known about the immune response of snakes to reptarenaviruses. In  
85 fact, the knowledge of the reptile immune response in general is scarce, mainly relying on  
86 individual studies undertaken on different species (21). It has been shown that like all  
87 vertebrates, reptiles mount an innate and adaptive immune response, comprising both humoral  
88 and cell-mediated factors (21, 22). Like in mammals, the humoral branch of the reptile innate  
89 immune system relies heavily on antimicrobial peptides and proteins as well as the  
90 complement pathway (21). Reptiles have equivalents of interleukins (IL), IFNs and Toll-like  
91 receptors and can therefore coordinate their immune response, however, *in vitro* studies show

92 the reptile system to be temperature and hormone dependent (21, 23–28). Also, in contrast to  
93 mammals with their cytokine-mediated development of fever, snakes are poikilotherm and  
94 thus increase their body temperature behaviourally by exposing themselves to higher  
95 environmental temperatures as demonstrated by stimulation with bacterial LPS or infection  
96 with gram-negative bacteria (21, 29, 30).

97 The adaptive immune response of both mammals and reptiles has a cell-mediated and a  
98 humoral component. The former is based on T cells, and in reptiles their proliferation depends  
99 on the seasonal cycle (31–33). Females show a stronger cell-mediated immunity than males in  
100 both mammals and reptiles (21, 34–36), and in the latter T cell proliferation is stronger in  
101 non-gravid than in gravid animals (21, 36). In vertebrates, including reptiles, the  
102 immunoglobulins (Ig) orchestrate the humoral branch of the adaptive immune system.  
103 Reptiles produce Igs of three classes, IgY, IgM and IgD; the leopard gecko (*Eublepharis*  
104 *macularius*), for example, also produces IgA (21, 37). The reptile IgM is considered as  
105 equivalent to IgM of other vertebrates, and IgY corresponds to mammalian IgG (22, 38); the  
106 molecular features are similar. Depending on the snake species IgY may occur in three  
107 isotypes, a, b, and c. According to sequence analysis, the IgY isotypes of boid snakes differ  
108 from those of other snake species but show structural similarity to mammalian IgG in that the  
109 heavy and light chains are covalently bound (37). In both reptiles and mammals exposure to  
110 an infectious agent (or other foreign antigen) triggers IgM production approximately within a  
111 week (21). In mammals IgM appears around 10 days (21) and peaks around 10-14 days post  
112 exposure. In reptiles, serum IgM levels reach the peak much later, up to 8 weeks post  
113 exposure, indicating differences in the maturation of the adaptive immune response compared  
114 to mammals (14, 21). Depending on the species studied and the antigens used, the IgM  
115 response in reptiles can last up to 34 weeks after exposure (21), whereas the IgY response  
116 appears around 31 days post exposure and can last for many years, similar to the mammalian  
117 IgG response (39).

118 Overall, in comparison to mammals, the reptile antibody response is weaker (22) since the  
119 titres do not necessarily increase after a second antigen exposure and there is a lack of affinity  
120 maturation (21, 22). However, studies on colubrid snakes indicated an increase in titres after  
121 repeated antigen exposure (40), and the rapidness of the response indicates immunological  
122 memory (21, 22, 40). Again, the reptile antibody response is affected by environmental and  
123 individual factors such as temperature, season, sex, age, and the neuroendocrine status (14,  
124 22).

125 We set up this study to assess the antibody response against reptarenaviruses in snakes  
126 with BIBD. Our working hypothesis was that snakes with BIBD would show low anti-  
127 reptarenavirus antibody titres, if any. We also wanted to study whether other measurable  
128 parameters, such as the sex, age, and weight of the animals, or the number of reptarenaviruses  
129 infecting an individual snake could be associated with IB formation. To answer these  
130 questions, we studied a cohort (N=70) of snakes in a single breeding collection with  
131 previously confirmed BIBD cases.

132

## 133 **RESULTS**

### 134 **Diagnosis of BIBD based on the cytological examination of blood smears**

135 We based the BIBD diagnosis on the detection of IBs in cells in blood smears stained with  
136 May-Grünwald-Giemsa (7). A similar approach was recently confirmed to correlate well with  
137 immunological staining of peripheral white blood cells (PWBC) for reptarenavirus NP (45).  
138 We could detect IBs (Figure 1) in 34 of the 70 blood smears studied (48.57%; BIBD-positive  
139 snakes; Table 1A). In the remaining 36 snakes (51.43%) the blood cells were free of IBs  
140 (BIBD-negative snakes; Table 1B) (2). At the time of blood sampling, all but the two  
141 debilitated snakes and the animal with cloacal prolapse (animals 1.18, 1.20, 1.29) appeared  
142 clinically healthy.

143 We examined the animals' age and weight against the BIBD diagnosis (Table 2). The  
144 average age was 4.6 years (95%CI: 4.26 – 4.99). We did not find statistically significant  
145 differences in age between female and male animals or between BIBD-positive and -negative  
146 animals. However, we found a statistically significant ( $p < 0.01$ ) association between BIBD  
147 and the weight of the female animals: BIBD-positive female animals had significantly lower  
148 body weights (Figure 2); the geometric mean of the weight was 3.077kg for the BIBD-  
149 positive female animals and 4.912 kg for the negative ones. The same association was not  
150 significant for male animals (Table 2). Linear regression established that the weight of the  
151 animals was significantly associated with age, sex and BIBD status (Table 3),  $F(3,63) =$   
152  $39.67$ , and they accounted for 63.74% of weight variability. The regression equation is:  
153  $\text{Predicted Weight} = -0.177 + 0.084 \text{ age} + 0.255 \text{ sex} - 0.107 \text{ BIBD-positive}$ .

### 154 **Characterization of the breeding collection's "reptarenavirome"**

155 We and others have previously reported that snakes with BIBD often harbour several  
156 reptarenavirus L and S segments; usually, more L than S segments are found in each snake (1,  
157 11, 12). To study whether the BIBD-negative snakes would also be free of reptarenavirus  
158 infection, we performed a meta-transcriptomic analysis of pooled blood samples (one pool



159 from three snakes without evidence of IBs in blood cells, the other from three snakes with a  
160 high number of IBs in blood cells). From the reads acquired by NGS of the BIBD-positive  
161 blood pool we could assemble five reptarenavirus L segments and one S segment, as well as  
162 two pairs of hartmanivirus L and S segments (10). To our surprise, we could not assemble any  
163 full-length L or S segments from the reads acquired from the BIBD-negative blood pool.  
164 However, using a mapping approach we identified some reads matching the L and S segments  
165 assembled from the data of the BIBD-positive blood pool. We then decided to screen a further  
166 three pools of three blood samples by RT-PCR, using virus-specific primers from our earlier  
167 study (1), one pool from BIBD-negative snakes, two from BIBD-positive snakes. We found  
168 the S segments of UGV-2, S5-like, and TSMV-2 to be present in the positive pools, while the  
169 negative pool was only positive for the latter two. The L segment profiles of the pools seemed  
170 variable.

171 We analysed the population parameters against the RT-PCR test results for associations  
172 with the detection of hartmaniviruses (OScV-1 and -2). OScV-1 detection did not  
173 significantly associate with any of the population parameters, while OScV-2 detection  
174 positively associated with age. The average age of animals without OScV-2 infection was  
175 4.28 years (n=50, 95%CI: 3.895 – 4.665), whereas it was 5.647 (n=17, 95%CI: 4.0260 –  
176 4.994) for OScV-2 positive snakes (t=-3.498, df: 65, p<0.05). None of the other population  
177 parameters showed any associations with OScV-2 after controlling for age. OScV-1 and -2  
178 detection showed poor to slight agreement with the other tests (Cohen's kappa < 0.2).

### 179 **Detection of reptarenavirus S segments in individual samples by RT-PCRs**

180 Reptarenaviruses require both segments to make infectious particles; therefore, we applied  
181 specific RT-PCR for the above identified three S segments to all animals to recognise the  
182 reptarenavirus infected, viraemic snakes. Of the 70 animals tested, we found 66 (94.3%) to  
183 exhibit reptarenavirus viraemia. Thirty snakes (42.9%) carried all three S segments examined  
184 (UGV-/S6-like, S5-like, and TSMV-2), and 32 (45.7%) carried two S segments. Of these, 21

185 snakes (30%) showed a combination of the S5-like and TSMV-2 S segments, nine snakes  
186 (12.9%) had the UGV-/S6-like and S5-like S segments, and two snakes (2.9%) had the UGV-  
187 /S6-like and TSMV-2 S segments. Of the four snakes with a single S segment, we found the  
188 UGV-/S6-like S segment in two, and the S5-like and TSMV-2 S segment in one snake each.  
189 The results are presented in detail in Table 1 and are summarised in Table 4.

190 We confirmed reptarenavirus viraemia in all BIBD-positive animals, and the majority  
191 (23/34; 67.65%) of these snakes carried all three S segments examined (UGV-/S6-like, S5-  
192 like, TSMV-2). Nine BIBD-positive snakes (26.47%) carried two S segments, and we  
193 detected only the UGV-/S6-like S segment in the remaining two animals (5.88%; animals  
194 1.07 and 1.23) (Tables 1 and 4). The UGV-like S segment was present in BIBD-positive  
195 animals.

196 In BIBD-negative snakes (N=36), we found all three viral S segments in seven snakes  
197 (19.4%), whereas 23 animals (63.9%) carried two S segments, and two snakes (5.56%) had a  
198 single S segment, one had the S5-like (animal 2.19) and the other the TSMV-2 (animal 2.22)  
199 S segment. Four snakes (11.1%) were negative for each S segment and deemed to be  
200 reptarenavirus-free (Tables 1 and 4).

201 Substantial agreement was identified between BIBD+ status and UGV-/S6-like S segment  
202 RT-PCR results (Cohen's  $\kappa=0.6878$ ). The agreement of the remaining RT-PCR tests with  
203 BIBD is slight (S5-like  $\kappa=0.1327$ , TMSV-2  $\kappa=0.1254$ , any segment detection  $\kappa=0.183$ , Table  
204 4). Sensitivity and specificity calculations are included in Table 4, though the study was not  
205 designed for such calculations.

206 We examined the associations of the RT-PCR results with population parameters (Table  
207 5). Female animals positive for the UGV-/S6-like S segment, as expected given the test  
208 agreement with the presence of IB, have a significantly lower body weight ( $t=2.99624882$ ,  
209  $df=34$ ,  $p<0.05$ ). For male animals the difference in weight is not significant. There is no  
210 significant difference in the age of UGV-/S6-like S segment RT-PCR-positive and -negative

211 animals or in their sex distribution. Multiple linear regression established that the age, sex and  
212 a positive UGV-/S6-like S segment RT-PCR result are significantly associated with the  
213 weight of the animals,  $F(3,63) = 36.98$ , and they accounted for 62.06% of weight variability.  
214 The regression equation is: Predicted Weight =  $-0.287 + 0.089 \text{ age} + 0.235 \text{ sex} - 0.086 \text{ UGV-}$   
215  $/\text{S6-like}$  indicating that the weight of UGV-/S6-like positive animals is lower than the weight  
216 of negative snakes after controlling for age and sex.

217 There is no significant difference in the age of S5-like S segment RT-PCR-positive and -  
218 negative animals but there are significantly more male positive animals ( $\chi^2=5.8019$ ,  $p<0.05$ ).  
219 The animals' weight is not significantly associated with a positive S5-like S segment RT-PCR  
220 result after controlling for sex and age. There is no significant difference in the age of TMSV-  
221 2 S segment RT-PCR-positive and -negative animals. There are though significantly more  
222 male animals positive for the TMSV-2 S segment ( $\chi^2=4.435$ ,  $p<0.05$ ). The animals' weight is  
223 not significantly associated with a positive TMSV-2 S segment RT-PCR result after  
224 controlling for sex and age.

225 Univariate analysis indicated that the number of S segments detected is not significantly  
226 associated with the age of the animals (ANOVA:  $F(6,66)=1.17$ ,  $p=0.333$ ). Male animals had  
227 significantly more S segments (mean = 2.559 [95%CI: 2.236 – 2.755]) than female animals  
228 (mean = 1.972 [95%CI:1.664 – 2.280]), ( $p<0.01$ ). Linear regression indicates that the number  
229 of segments is negatively associated with the weight of the animals ( $F(1,68)=8.83$ ,  $R^2 =$   
230  $0.103$ , Predicted weight =  $0.696 - 0.106 \text{ number of segments}$ ,  $p<0.01$ ). When the confounding  
231 effect of sex was examined by stratifying for sex, no significant association was identified  
232 between the number of S segments and the animals' weight. There is a positive association  
233 between the number of segments and the detection of IB in blood cells. The mean number of  
234 segments for BIBD-positive animals is 2.618 (95%CI: 2.407 – 2.828) and for BIBD-negative  
235 animals 1.917 (95%CI: 1.632 – 2.201) ( $p<0.001$ ).

236 **Antibody response against reptarenavirus NP**

237 So far, not much is known about the antibody response against reptarenaviruses in snakes.  
238 In our first report on identification of reptarenaviruses in snakes with BIBD, we used an  
239 indirect ELISA to indicate that there might be antibodies in some snakes with BIBD (7). In a  
240 more recent study, we generated tools for the detection of IgM and IgY class antibodies in  
241 boas, and, using immunofluorescence and western blot, demonstrated that some BIBD-  
242 positive snakes have antibodies against reptarenavirus NP (14).

243 Antibody detection by western blot (WB)

244 We studied the plasma samples of the entire collection using WB as the detection tool, and  
245 used concentrated UGV-1 virions as the antigen. The main protein component of the virions  
246 is NP, which is why we interpret the signals as anti-NP IgY and IgM. The signal intensities  
247 varied and we applied the following grading: negative (-), weakly positive (+), moderately  
248 positive (++), and strongly positive (+++); the WB result for each snake is included in Table  
249 1. Among the 34 BIBD-positive snakes, we found five (14.7%) negative for both anti-NP IgY  
250 and IgM, whereas 20 snakes (58.8%) had both anti-NP IgM and IgY antibodies, and nine  
251 (26.5%) had either anti-NP IgY (N=4) or IgM (N=5). Ten snakes were anti-NP IgY-negative  
252 and nine were anti-NP IgM-negative. The 36 BIBD-negative snakes included 22 (61.1%) anti-  
253 NP IgY- and IgM-positive snakes, eight (22.2%) were positive for either anti-NP IgY (N=3)  
254 or IgM (N=5), six (16.7%) were negative for both. Eleven snakes were anti-NP IgY-negative  
255 and nine anti-NP IgM negative. Within the entire collection 11 snakes were negative for both  
256 anti-NP IgY and IgM antibodies. There are no significant associations of WB results for NP  
257 IgY or IgM and any of the population parameters.

258 The WB results for anti-NP IgY and IgM in relation to BIBD are summarised in Table 6.  
259 The agreement of the WB results with BIBD is slight for anti-NP IgY (Cohen's  $\kappa=0.0294$ )  
260 and poor for IgM ( $\kappa=0.0000$ ). As for the RT-PCR results we included indicative sensitivity  
261 and specificity calculations. The sensitivity of the IgY WB in detecting BIBD is 70.6%

262 (95%CI: 59.8% – 81.4%) and the specificity 32.4% (95%CI:21.2% – 64.3%). For IgM, the  
263 WB sensitivity is 73.5% (95%CI:63.0% - 84.0%) and the specificity 26.5% (95%CI:16.0% -  
264 37.0%). We examined the agreement of the BIBD status against the graded WB results using  
265 Cohen's weighted kappa( $\kappa(w)$ ). For anti-NP IgY  $\kappa(w)$  is 0.0119 and for IgM  $\kappa(w)$  is 0.000  
266 indicating slight and poor agreement, respectively. We also examined the agreement between  
267 WB results and RT-PCR results using Cohen's kappa for binary WB results and weighted  
268 kappa for graded WB results. In all cases the agreement was slight or poor. For anti-NP IgY  
269 WB results in relation to UGV-2 RT-PCR Cohen's  $\kappa = -0.195$  and  $\kappa(w) = -0.074$ ; in relation  
270 to S5-like PT-PCR Cohen's  $\kappa = 0.024$  and  $\kappa(w) = 0.008$ ; in relation to SMTV-2 RT-PCR  
271 Cohen's  $\kappa = 0.088$  and  $\kappa(w) = 0.03$ . For anti-NP IgM WB results in relation to UGV-2 RT-  
272 PCR Cohen's  $\kappa = 0.067$  and  $\kappa(w) = -0.024$ ; in relation to S5-like RT-PCR Cohen's  $\kappa = 0.061$   
273 and  $\kappa(w) = 0.02$ ; in relation to SMTV-2 RT-PCR Cohen's  $\kappa = 0.069$  and  $\kappa(w) = 0.024$ .

#### 274 Antibody detection by ELISA

275 Since the quantification of WB results is at best indicative of the antibody titres, we  
276 decided to set up an ELISA test for the detection of anti-reptarenavirus NP antibodies. We  
277 used purified UGV-1, recombinant UHV-1 NP, and the C-terminal portion of UHV-1 NP  
278 (UHV-1 NP-C) as the antigens.

#### 279 ELISA results as quantitative variables

280 We examined the ELISA results against the BIBD status and the RT-PCR results using t-  
281 test. UGV-1 IgY ELISA OD values were significantly higher for BIBD- ( $p < 0.001$ ) and UGV-  
282 2 RT-PCR- ( $p < 0.05$ ) negative animals, whereas UGV-1 IgM ELISA OD values were  
283 significantly higher for BIBD-positive animals ( $p < 0.05$ ). UHV-1 NP IgY ELISA OD values  
284 were significantly higher for BIBD- ( $p < 0.001$ ) and UGV-2 RT-PCR- ( $p < 0.01$ ) negative  
285 animals, UHV-1 NP-C IgY ELISA OD values were significantly higher for BIBD ( $p < 0.01$ )  
286 and UGV-2 RT-PCR ( $p < 0.01$ ) negative animals, and UHV-1 NP-C IgM ELISA OD values  
287 were significantly higher for BIBD- ( $p < 0.05$ ) and UGV-2 RT-PCR- ( $p < 0.01$ ) negative

288 animals and for SMTV-2 RT-PCR-positive animals ( $p < 0.05$ ). Table 7 provides the detailed  
289 results of the analysis.

290 ELISA results for IgY and IgM from all the tests were analysed against population  
291 parameters and the other tests. At univariate level we used Analysis of Variance (ANOVA) to  
292 examine associations between age and antibody titres. UGV-1 IgY ELISA titres were the only  
293 ones significantly associated with age ( $F(6,59) = 3.52$ ,  $p < 0.01$ ). Linear regression established  
294 that weight was significantly associated with ELISA titres for UGV-1 IgY and UGV-1 IgM  
295 (Regression equations UGV-1 IgY:  $F(1,67) = 32.4$ ,  $R^2 = 0.326$ , Predicted UGV-1 IgY =  $-1.245$   
296 +  $1.556$  weight; Predicted UGV-1 IgM:  $F(1,67) = 4.9$  =  $-0.217 - 0.188$  weight). There was no  
297 significant association between any of the ELISA test results and the animals' sex. The results  
298 of the univariate analysis are presented in Table 8.

299 Using multivariable linear regression, we examined the associations of UGV-1 IgY and  
300 IgM with BIBD, weight and age. We established that both age and BIBD+ status were  
301 significantly associated with UGV-1 IgY antibody titres,  $F(2,63) = 16.94$ , and they accounted  
302 for 32.90% of antibody variability ( $p < 0.001$ ). The regression equation is: Predicted UGV-  
303 IgY OD(log10) =  $-1.147 + 0.181$  age -  $0.4812$  BIBD+. Figure 3A illustrates this association,  
304 with BIBD-negative animals demonstrating higher antibody titres than BIBD-positive ones. A  
305 similar model when fitted for UGV-1 IgM did not provide significant results. We include the  
306 graphic representation (Figure 3B) as the result may indicate an interesting trend of UGV-1  
307 IgM remaining at higher levels for BIBD-positive animals because of continuous exposure  
308 from circulating virus while in BIBD-negative snakes, lack of such exposure may lead to  
309 UGV-1 IgM reduction in older animals. Figure 3 (A-F) demonstrates the association of all the  
310 ELISA test results with age and IB detection.

311 Multivariable linear regression also established that age, sex and plasma UGV1 IgY were  
312 significantly associated ( $p < 0.0001$ ) with the weight of the animals,  $F(3,62) = 38.24$  and they  
313 accounted for 63.22% of weight variability. The regression equation is: Predicted Weight =

314  $0.079 + 0.075 \text{ age} + 0.195 \text{ sex} - 0.096 \text{ UGV1 IgY OD}$ . Figure 4 demonstrates this association  
315 separately for male and female animals. To establish linearity in this and all previous cases,  
316 we checked the residuals for normalcy using Shapiro-Wilk test and examined a residual  
317 versus fitted values plot.

318 We then investigated the potential association between the number of S segments found  
319 and the antibody response. Of the 23 BIBD-positive snakes in which all three viral S  
320 segments were detected, six (26.09 %) were positive for anti-UGV IgY and 14 (63.64 %) for  
321 anti-UGV IgM antibodies, four (18.18 %) carried both IgY and IgM, and seven (31.82%)  
322 were negative for either antibodies. Among the nine snakes with two S segments were two  
323 (22.22 %) that exhibited anti-UGV IgY antibodies, and three (33.33 %) were positive for anti-  
324 UGV IgM antibodies. The two IgY-positive snakes also carried anti-NP IgM antibodies  
325 (22.22%); six snakes (66.67 %) were negative for either antibodies. Both BIBD-positive  
326 snakes in which only the UGV-/S6-like S segment was detected exhibited an anti-NP IgM  
327 response; one also carried anti-NP IgY antibodies. All seven BIBD-negative animals tested  
328 positive for three viral S segments carried UGV-specific antibodies, five (71.43%) were IgY-  
329 positive, and three (42.86 %) IgM-positive, one snake (14.29%) was positive for both Igs. Of  
330 the animals positive for two S segments (n=23), the majority carried IgY (n=14; 60.87%),  
331 nine (39.13%) were IgM-positive, and five (21.74%) were positive for both antibodies; five  
332 animals (21.74%) did not exhibit an antibody response. Both snakes in which a single viral S  
333 segment was detected exhibited both an IgY and an IgM response. Of the four RT-PCR  
334 negative animals, two (50%) showed a combined IgY and IgM response, one only had IgY  
335 antibodies, and one did not exhibit an anti-reptarenavirus response. There is no significant  
336 association between the number of segments and any of the ELISA results.

### 337 ELISA cut-off points

338 The background corrected raw ELISA data with cut-off values are presented in Figure 5.  
339 We tested the BIBD-positive snakes for the presence of anti-UGV-1 IgY and IgM antibodies

340 and found nine (26.5%) IgY positives and 19 (57.58%) IgM positives of which seven  
341 (21.21%) were also IgY-positive. Thirteen animals (39.39%) did not exhibit any anti-UGV-1  
342 antibodies (Table 9A). Of the 36 BIBD-negative snakes 24 (66.67 %) had anti-UGV-1 IgY  
343 and 16 (44.44%) anti-UGV-1 IgM antibodies, 10 animals (27.78%) showed both IgY and  
344 IgM; six snakes (16.67%) did not exhibit any anti-UGV-1 antibodies (Table 9B).

345 Within the group of BIBD-positive snakes were six (17.65%) that carried anti-UHV-1-NP  
346 IgY and seven (20.59%) positive for IgM. Four snakes (11.76%) carried both antibodies and  
347 25 (73.53%) did not exhibit any anti-UHV-1 antibodies. The examination of UHV-1-NP  
348 antibodies in the BIBD-negative group identified 17 snakes (47.22%) with IgY and nine  
349 (25%) with IgM antibodies. A combination of IgY and IgM was detected in eight snakes  
350 (22.22%), whereas 18 (50%) were negative for both anti-UHV-1-NP antibodies. Of the  
351 BIBD-positives snakes seven (20.59%) had anti-UHV-1-NP-C IgY and 10 (29.41%) IgM  
352 antibodies. Both antibodies were found in five snakes (14.71%) and 22 (64.71%) were  
353 negative for IgY and IgM. Among the BIBD-negative animals 19 (52.78%) carried IgY and  
354 17 (47.22%) were positive for IgM of which 16 (44.44%) also exhibited an IgY antibody  
355 response; 16 snakes (44.44%) did not carry any anti-UHV-1-NP-C antibodies.

356 We examined the agreement of the different ELISA tests with the BIBD status using  
357 Cohen's kappa (Table 10). Because significantly more BIBD-positive animals were testing  
358 negative for IgY (above the cut-off point, see Table 1), and because the measured OD values  
359 in ELISA were lower in BIBD-positive than in BIBD-negative animals we calculated the test  
360 agreement, using Cohen's kappa, considering negative ELISA results equivalent to positive  
361 BIBD ones. We reversed thus the UGV-1 IgY ELISA results (positive to negative) which led  
362 to a moderate agreement with BIBD ( $\kappa=0.429$ ). The same applied to UHV-1 NP IgY ELISA  
363 ( $\kappa = 0.293$ ) and UHV NP-C IgY ( $\kappa=0.319$ ) which showed fair agreement with BIBD. All IgM  
364 ELISA results show slight or poor agreement with BIBD (UGV-1 IgM,  $\kappa = 0.131$ ; UHV-1 NP  
365 IgM,  $\kappa = -0.045$ ; UHV1 NP-C IgM,  $\kappa = -0.179$ ). Results are summarised in Tables 10 and 11



366 including the agreement between ELISA results and RT-PCR. All results indicate poor to fair  
367 agreement between tests. 95% confidence intervals were calculated for Cohen's kappa and  
368 further confirm the lack of agreement between tests (44).

369 Using univariate analysis, we examined the ELISA test results based on the cut-off points  
370 for associations with population parameters. There is no significant association between  
371 animal sex and any of the ELISA results. The presence of UGV-IgY is significantly  
372 associated with weight. The geometric mean (GM) weight of UGV-IgY-positive animals  
373 (n=34) is 3.809 kg (95% CI: 3.159 – 4.594) while for UGV-IgY-negative animals (n=36) the  
374 geometric mean weight is 2.193 kg (95%CI: 1.858 – 2.589kg,  $p < 0.0001$ ). This association  
375 remained significant after stratification for sex for both male and female animals (Male:  
376 UGV-IgY positive animals (n=14) GM=2.448 kg [95%CI: 1.995 – 3.004], UGV-IgY negative  
377 animals (n=20) GM=1.809 kg [95%CI: 1.484 – 2.206],  $p < 0.05$ ; Female: UGV-IgY positive  
378 animals (n=16) GM=5.192 kg [95%CI: 4.283 – 6.293 ], UGV-IgY negative animals (n=20)  
379 GM=2.788 kg [95%CI: 2.167 – 3.588],  $p < 0.001$ ). A significant association was also identified  
380 between UGV-IgY and the animals' age. UGV-IgY-positive animals are significantly older  
381 than negative animals ( $p < 0.001$ ). The average age is 5.313 years (95%CI: 4.783 – 5.842) and  
382 4 years (95%CI: 3.567 – 4.329) for UGV-IgY positive animals (n=32) and negative animals  
383 (n=35) respectively. After stratifying for sex, the association remained significant for female  
384 animals (UGV1 IgY positive animals (n=20) mean age=5.5 years) [95%CI: 4.865 – 6.135];  
385 UGV-IgY negative (n=16) mean age=4.063 years [95%CI: 3.568 – 4.557],  $p < 0.005$ ). No  
386 other association was identified between any of the ELISA results based on the cut-off point  
387 and population parameters. All the results are presented in Table 12.

388

389

## DISCUSSION

390 In this study, we investigated the association between BIBD, pathogen detection,  
391 population parameters and serological findings in a cohort of snakes from one breeding  
392 colony. As our previous studies had implied an association between BIBD and low antibody  
393 levels (7, 14), the main focus of this study was on a potential link between anti-reptarenavirus  
394 antibody levels and BIBD. We hypothesised that some reptarenavirus S segments can be  
395 found more frequently in snakes with BIBD, and that healthy and diseased snakes would  
396 show different S segment profiles. We examined a panel of 70 blood samples, evenly  
397 distributed by sex, collected on the same day from the entire animal cohort. Because snakes  
398 are poikilotherm, we considered minimising the environmental influence on the immune  
399 response to be essential. Therefore, the study was restricted to a single breeding colony where  
400 animals are kept under virtually the same husbandry conditions with regards to moisture,  
401 light, feeding regime and temperature, except that male snakes are kept at 2-5 °C lower  
402 temperatures than females to increase reproductive activity.

403 We started by dividing the sample panel in BIBD positives and negatives based on the  
404 detection of IBs in blood cells, using blood smears stained under quality controlled  
405 conditions. The examination of population parameters in our study did not show an  
406 association of age and the presence of IB, suggesting that the time and duration of the  
407 infection would not be a factor in the development of BIBD, though this is highly speculative  
408 as data on, for example, the introduction of individual animals was not available. Also, a  
409 dependency of sex and BIBD could not be shown, but we could demonstrate a statistically  
410 significant association between BIBD and reduced body weight in female snakes. While this  
411 may reflect the low number of snakes included in the study, it might also be indicative of  
412 metabolic or behavioural changes in the infected snakes. Since reptarenaviral replication is  
413 temperature sensitive (46), one could also speculate reptarenaviruses replicate more  
414 efficiently in female snakes as these are housed at slightly higher temperatures. Further

415 studies on the optimal reptarenavirus replication temperature would be required to address  
416 this hypothesis.

417 By NGS and de novo genome assembly, we identified two pairs of hartmanivirus L and S  
418 segments, several reptarenavirus L segments but only a single reptarenavirus S segment  
419 (UGV-like) from the RNA of a BIBD-positive blood pool (10). Interestingly, reads matching  
420 reptarenaviruses were clearly less abundant in the RNA sample extracted from the BIBD-  
421 negative blood. This finding could indicate higher replication or more intense viraemia in the  
422 BIBD-positive snakes, however, it could also be explained by unknown factors related to  
423 library preparation. As we aimed to study the immune response using NP as the antigen, we  
424 used the S segment primers of our previous study (1) in RT-PCRs to screen the pools, and  
425 identified two additional S segments (S5-like and TSMV-2) within the pools. Screening of all  
426 individual samples for UGV-like, S5-like, and TSMV-2 S segments by RT-PCR showed that  
427 97.1% of the BIBD-positive snakes carried the UGV-like S-segment. This observation is well  
428 in line with previous studies, in which we (1, 11) and others (12) have observed that UGV-  
429 /S6-like S segments are often found in snakes with BIBD. In contrast, we found the UGV-  
430 /S6-like S segment only in 27.8% of the BIBD-negative snakes. As the mechanisms behind IB  
431 formation are still unknown, one could speculate that UGV-/S6-like NP would be more prone  
432 to IB formation. However, in our first report on reptarenaviruses in snakes, we purified IBs  
433 from infected cell cultures and used peptide mass fingerprinting to identify the main protein  
434 component as University of Helsinki virus-1 (UHV-1) NP. This finding suggests that IB  
435 formation is similar between different reptarenavirus species (or S segments). Thus one  
436 explanation on why UGV-/S6-like S segments are often found in snakes with BIBD could  
437 instead lie in the GPC that is also carried in the S segment. The origin and reservoir host(s) of  
438 reptarenaviruses remain unknown, however, it seems obvious that UGV-/S6-like GPC allows  
439 the virus to spread efficiently among boas. As IBs are found in various tissues, the UGV-/S6-  
440 like GPC could also allow wide tissue tropism. Our findings indicated that detection of UGV-

441 /S6-like S segment had the closest substantial agreement ( $\kappa=0.6878$ ) with BIBD. However,  
442 further work will be required to establish the sensitivity and specificity of UGV-/S6-like S  
443 segment detection in BIBD diagnosis.

444 The reptile immune response is not known in great detail, and its description is often  
445 subjected to a comparison with the mammalian immune system. It is also unclear how much  
446 immune response mechanisms vary within the class Reptilia or even within the clade Ophidia  
447 inside the order Squamata since studies on the immune response of snakes partially report  
448 controversial findings, for instance regarding the increase in titres after repeated antigen  
449 exposure in colubrid snakes (40). Also, different IgY isotypes of certain snake species have  
450 been described (37), and a secretory immunoglobulin has only been found in the bile of the  
451 northwestern garter snake (*Thamnophis ordinoides*) (47). The fact that we studied samples  
452 collected at a single time point from naturally infected snakes for which the time of infection  
453 was unknown, made the evaluation of antibody response kinetics impossible. However, the  
454 analysis of IgY and IgM antibodies by WB and ELISA showed that the presence of anti-UGV  
455 NP IgY is negatively correlated to the presence of IB and thereby BIBD (Figure 2). Assuming  
456 that there is a correlation between anti-NP and anti-glycoprotein response (since they come  
457 from the same segment), our results would suggest that IgY could provide protective  
458 immunity. Further evidence of a possible association between infection with a virus bearing  
459 UGV-/S6-like S segment and BIBD is the observation that we found a significant positive  
460 association between weight and plasma UGV1 IgY titres. The observed variable occurrence  
461 of IgY and IgM antibodies in individual snakes could be due to the prolonged persistence of  
462 IgM and the variable onset of IgY production (21, 39). Anti-UGV NP IgM antibody titres  
463 showed a trend to lower in the older BIBD-negative snakes, which could reflect exhaustion of  
464 the immune system or a gradual class switch towards IgY. The current knowledge on the role  
465 of IgM and its age dependency in protective immunity in snakes is scarce. Natural antibodies  
466 (NAbs) are thought to compensate the decreasing sensitivity of the adaptive immune system

467 in ageing snakes (48). Interestingly, NAbs are also suggested to provide protection against  
468 mammarenavirus (LCMV) infection by epitope recognition (49). The timing of infection has  
469 great influence on the immune response, as shown for LCMV, the prototypic arenavirus.  
470 Infection *in utero* or as a neonate results in chronic infections (1, 50). However, despite the  
471 assumption that persistently infected LCMV carriers can develop a state of tolerance,  
472 accepting the virus as endogenous, and therefore do not respond by antibody production (51),  
473 studies demonstrated an immunological response towards LCMV and concluded that low  
474 antibody levels were due to the formation of immune complexes (52). In addition, several  
475 studies elucidated a dependency of antibody production on different strains of viruses and  
476 mice and a different IgG isotype profile in chronic vs. acute infections of mice (53). These  
477 were attributed to involvement of different T cell populations, and associated with varying  
478 clinical signs (53). Exhaustion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells is associated with chronic LCMV  
479 infection in mice, and the functional impairment of CD4<sup>+</sup> T cells also has a negative impact  
480 on the antibody response (54, 55). The production of antibodies is reduced by exhaustion of  
481 CD4<sup>+</sup> T cells but can be reversed by providing virus-specific CD4<sup>+</sup> T cells from transgenic  
482 mice into chronically infected animals (54). Mice persistently infected with LCMV do not  
483 possess LCMV-specific CD8<sup>+</sup> T cells (53) and CD4<sup>+</sup> T cells are absent in transplacentally  
484 infected mice (55). The attenuation of T cell dependent immune functions as well as immune  
485 complex formation support the assumption that animals infected via vertical transmission  
486 show lower antibody levels than horizontally infected animals. It is possible that vertical  
487 transmission also occurs for maternal antibodies in ovoviparous snakes, such as *B.*  
488 *constrictor*. This could theoretically compensate for the embryo's immunological  
489 incompetence; however, how this aligns with the fact that persistently infected mothers pass  
490 both their reptarena- (1) and hartmaniviruses (10) to the newborn is not clear. Many snakes  
491 examined in the present study are related, as they represent a breeding colony; therefore, it is  
492 not possible to determine how many were horizontally infected. It is tempting to speculate

493 that the snakes with high antibody titres were horizontally infected, whereas the BIBD-  
494 positive animals with low antibody titres were vertically infected. This would tie in with  
495 observations on the prototype arenavirus, LCMV, which leads to reduced levels of IgG2a  
496 subclass in persistently infected mice (53). In addition to the antibody response,  
497 reptarenaviruses can be expected to influence the innate immune system in a manner similar  
498 to that of mammarenaviruses i.e. via inhibition of type I interferon production (10, 17, 18,  
499 56). Indeed, a general reptarenavirus-induced immunosuppression would tie in with the  
500 increased incidence of bacterial infections and/or neoplastic processes in snakes with BIBD  
501 (2–4).

502 This is to our knowledge the first report to thoroughly assess the adaptive immune  
503 response of boid snakes towards reptarenaviruses. By characterising a single breeding  
504 collection, we could demonstrate that one individual virus, UGV-/S6-like S segment, was  
505 strongly associated with BIBD. Supporting the link between the presence of UGV-/S6-like S  
506 segment and BIBD, we found a negative correlation between BIBD and the presence of anti-  
507 UGV NP antibodies. Future studies, either longitudinal or experimental infection driven, are  
508 needed to understand the kinetics of the antibody response in snakes with reptarenavirus  
509 infection. Our results do, however, suggest that presence/absence of UGV-/S6-like S segment  
510 RNA and presence/absence of anti-UGV NP IgY antibodies could serve to a limited extent in  
511 the *ante mortem* diagnostics of BIBD.

512

513

## MATERIALS AND METHODS

### 514 **Study cohort and samples, cytological examination**

515 We studied a breeding collection of 70 *Boa constrictor* snakes comprising 36 female and  
516 34 male adult individuals, aged between two and eight years (Table 1). Husbandry conditions  
517 included humidity of approximately 60% and a season-dependent light regime with  
518 photoperiods of 12-13 hours during warm and 9-10 hours during cold months. Female snakes  
519 were kept at an environmental temperature of 26-33 °C with a drop of 3-4 °C during night,  
520 but not deceeding 24 °C whereas the males were kept at an environmental temperature  
521 approximately 2-5 °C lower than the females with a minimum temperature of 23 °C The  
522 cohort included two debilitated snakes (one male, animal 1.20; one female, animal 1.29) and  
523 one female snake with cloacal prolapse (animal 1.18); the remaining animals were clinically  
524 healthy. In June 2015, one snake from the collection had been euthanised due to clinical signs,  
525 and post mortem examination had confirmed BIBD diagnosis. Subsequent analysis of blood  
526 samples from 14 snakes had revealed the presence of cytoplasmic IBs in blood cells of eight  
527 snakes, confirmed that they also suffered from BIBD. These findings prompted the owner to  
528 have the entire breeding colony tested for BIBD a year later. In July 2016, blood samples  
529 were collected in 1.3 ml K3E EDTA tubes (Sarstedt) by either caudal tail vein venipuncture  
530 or cardiocentesis. All snakes were weighed before bleeding. No ethical permissions were  
531 required for these diagnosis-motivated blood samplings.

### 532 **Blood samples and smears**

533 Cytological examination of blood smears, which presents the current standard *ante mortem*  
534 diagnostic tool (3, 41), served to confirm BIBD diagnosis. We prepared two blood smears for  
535 each animal, stained with May-Grünwald-Giemsa, and used light microscopy for IB detection  
536 in blood cells as described (1). From the remaining blood, ca. 1 ml each, we separated plasma  
537 by centrifugation at 1,200 g for 2 min, and stored the cell-enriched blood and plasma at -80  
538 °C.

539 **Next generation sequencing (NGS)**

540 NGS served to identify the “reptarenavirome” of the breeding collection, and to allow the  
541 setting up of virus-specific RT-PCRs for screening of the entire collection. For NGS, we  
542 prepared two pooled samples of cell-enriched blood: 1. three snakes without evidence of  
543 BIBD (no IBs in blood cells), 2. three snakes with confirmed BIBD (abundant IBs in blood  
544 cells), and performed RNA extraction, NGS library preparation, and genome assembly as  
545 described (1, 42).

546 **Reverse transcriptase-polymerase chain reaction (RT-PCR)**

547 We were interested in sequencing the S segments present in the breeding colony, since the  
548 S segment bears the NP which we used as the antigen in the antibody assays. As we only  
549 recovered a single complete reptarenavirus S segment (University of Giessen virus-1, UGV-1,  
550 GenBank accession MH483061) by NGS and *de novo* assembly (10), we decided to use the  
551 virus-specific primers of our previous study (1) to screen three additional RNA pools  
552 prepared from blood samples by RT-PCR: one BIBD-negative (no evidence of IB in blood  
553 cells) and two BIBD-positive. By this approach, we detected: University of Giessen virus-like  
554 (UGV-2 and UGV-3, primers (1)), S5-like (S5-like, primers (1)), and Tavallinen suomalaisen  
555 mies virus-2 (TSMV-2, primers (1)) S segments in the BIBD-positive RNA pools; and S5-like  
556 and TSMV-2 S segments in the BIBD-negative RNA pool. We then used these three primer  
557 pairs to screen blood samples of the entire collection by RT-PCR. Additionally, we screened  
558 the collection by RT-PCR with primers targeting the L segments of two hartmaniviruses  
559 identified by NGS and *de novo* assembly in the BIBD positive pool, i.e. Old Schoolhouse  
560 viruses 1 and 2 (OScV-1, OScV-2) described in a previous study (10).

561 We did RNA extractions from cell-enriched EDTA blood (100 µl) as described (1), but  
562 introduced a mechanical homogenization step using a Retsch MM300 TissueLyser  
563 (QIAGEN) for 2 min at highest frequency (30 Hertz). The



564 following primers were used: UGV-2 and -3 S segment (Fwd 5'-  
565 ATAAGGTCAGGGTATAACTTGG-3' and Rev 5'-  
566 GAACTTGGCATAAAAATACAAATGAATG-3'), S5-like S segment (Fwd 5'-  
567 GTCAGGATAGAGTCTGGGAGCAT-3' and Rev 5'-  
568 TGAACATTCAGAGGGAATTTGGCATC-3'), TSMV-2 S-segment (Fwd 5'-  
569 CAAGTCTGGATAAAGTCTTGGTGCAT-3' and Rev 5'-  
570 GTAATTGATGACGACAATAGGGTCGA-3'), OScV-1 L segment (Fwd 5'-  
571 GCACTAAGTGGATCATCAAC-3' and Rev 5'- CATGCAAACCTGTTGCTG-3'), and  
572 OScV-2 L segment (Fwd 5'- GCACTAAGTGGATCATCAAC-3' and Rev 5'-  
573 GAACAATGTCATAACTTGCTC-3'); RT-PCR was performed as described (1), the  
574 amplicons analysed by agarose gel electrophoresis, and the bands visualised by GelRed  
575 Nucleic Acid Gel Stain (BIOTIUM) under UV-light with the UVP BioDoc-It Imaging  
576 System (Thermo Fisher Scientific). The GeneRuler 100 bp DNA ladder (Thermo Fisher  
577 Scientific) served as the marker.

#### 578 **Western blot (WB)**

579 We used UGV-1 virions concentrated by ultracentrifugation through a sucrose cushion,  
580 prepared as described in (7), as the antigen in WB. We did the WBs with plasma samples as  
581 described in (14), but blocked the nitrocellulose membranes for 3-4 h instead of 30 min at  
582 room temperature. We used snake plasma at 1:200 dilution, and the affinity purified  
583 unlabelled anti-IgM and anti-IgY antibodies (14) at respective dilutions of 1:500 and 1:1000.  
584 We evaluated the results recorded using the Odyssey CLx Infrared Imaging System (LI-COR  
585 Biosciences) as negative (-), weakly positive (+), moderately positive (++), and strongly  
586 positive (+++) according to the signal intensity.

#### 587 **Enzyme-linked immunosorbent assay (ELISA)**

588 We set up an ELISA to measure the IgM and IgY levels in the plasma samples using  
589 concentrated UGV-1 virions (inactivated with 1% Triton X-100 [Fluka BioChemika]), and

590 recombinant UHV-1 NP and UHV-1 NP-C (described in (43)) as the antigens. We diluted the  
591 antigens (UGV-1 at 1:400, UHV-1 NP and UHV-1 NP-C at 2 µg/ml) in 0.05M carbonate  
592 buffer, pH 9.6, and used 100 µl/well to coat Nunc Microplate Immuno Polysorp (Thermo  
593 Scientific) plates by overnight incubation on an orbital shaker at 4 °C. After coating, we used  
594 1% BSA in PBS (150 µl/well) for blocking (2 h at 37 °C), washed once with TBS-T (TBS +  
595 0.05% Tween-20) prior to incubation (1 h at 37 °C) with the plasma samples diluted (1:200  
596 used for UHV-1 NP-C, and 1:400 for UHV-1 NP and UGV-1) in 0.25% BSA/PBS. After four  
597 TBS-T washes, we incubated (45 min at 37 °C) the plates with 100 µl/well of horseradish  
598 peroxidase (HRP) labelled anti-boa IgM or anti-boa IgY antibodies, described in (14), diluted  
599 1:2000 in 0.25% BSA/PBS, washed four times with TBS-T, incubated (20 min at RT) with  
600 TMB Substrate Solution (Thermo Scientific) 100 µl/well, terminated the reaction by addition  
601 of 1M H<sub>2</sub>SO<sub>4</sub> 50 µl/well, and read the results (OD at 450 nm) with a BioTek Synergy HT  
602 Multi-Mode Microplate Reader.

603 We performed change point analysis utilising the changepoint v.2.2.2 package  
604 (<https://rdrr.io/cran/changepoint/>) in R to set the cut-off values (separately for IgM and IgY  
605 and for each antigen) for distinguishing positive and negative ELISA results. Briefly, we used  
606 the cpt.meanvar function with the AMOC method on the ELISA data arranged in ascending  
607 order. We set the cut-offs (UHV NP IgY=0.31; UHV NP IgM=0.35; UGV-1 IgY=0.27; UGV-  
608 1 IgM=0.48; UHV NP-C IgY=0.47; and UHV NP-C IgM=0.37) just above the detected  
609 change point, so that the value at change point was considered negative.

## 610 **Statistical analysis**

611 We performed data analysis using Stata Statistical Software: Release 13. College Station,  
612 TX: StataCorp LP. The analysis examined possible associations between test results and  
613 population parameters using univariate and multivariable analysis. For data that were not  
614 normally distributed, we utilised non-parametric tests. Given the nature of the investigation

615 and the study population, the analysis is predominantly descriptive. Sensitivity and specificity  
616 calculations for the different tests were used as indicative since the study was not designed for  
617 the purpose. Cohen's kappa ( $\kappa$ ) and weighted kappa  $\kappa$  (w) served to examine the agreement  
618 between tests with binary or ordinal data (44).

619

## ACKNOWLEDGEMENTS

620 The authors are grateful to the snake breeder who provided us with the case material for  
621 the present study. They also thank the laboratory staff of the histology laboratory (Institute for  
622 Veterinary Pathology, Vetsuisse faculty, University of Zürich) for excellent technical support.  
623 The study received financial support from the Schweizerische Vereinigung für Wild-, Zoo-  
624 und Heimtiermedizin (SVWZH) and the Academy of Finland (grant numbers 1308613 and  
625 1314119).

626

627

- 629 1. Keller S, Hetzel U, Sironen T, Korzyukov Y, Vapalahti O, Kipar A, Hepojoki J. 2017.  
630 Co-infecting Reptarenaviruses Can Be Vertically Transmitted in Boa Constrictor. *PLoS*  
631 *Pathog* 13:e1006179.
- 632 2. Schumacher J, Jacobson ER, Homer BL, Gaskin JM. 1994. Inclusion Body Disease in  
633 Boid Snakes. *Journal of Zoo and Wildlife Medicine* 25:511–524.
- 634 3. I-W C, Jacobson E. 2010. Inclusion Body Disease, A Worldwide Infectious Disease of  
635 Boid Snakes: A Review. *Journal of Exotic Pet Medicine* 19.
- 636 4. Wozniak E, McBride J, DeNardo D, Tarara R, Wong V, Osburn B. 2000. Isolation and  
637 characterization of an antigenically distinct 68-kd protein from nonviral intracytoplasmic  
638 inclusions in Boa constrictors chronically infected with the inclusion body disease virus  
639 (IBDV: Retroviridae). *Vet Pathol* 37:449–459.
- 640 5. Bodewes R, Kik MJL, Raj VS, Schapendonk CME, Haagmans BL, Smits SL, Osterhaus,  
641 A D M E. 2013. Detection of novel divergent arenaviruses in boid snakes with inclusion  
642 body disease in The Netherlands. *J Gen Virol* 94:1206–1210.
- 643 6. Stenglein MD, Sanders C, Kistler AL, Ruby JG, Franco JY, Reavill DR, Dunker F,  
644 Derisi JL. 2012. Identification, characterization, and in vitro culture of highly divergent  
645 arenaviruses from boa constrictors and annulated tree boas: candidate etiological agents  
646 for snake inclusion body disease. *MBio* 3:e00180-12.
- 647 7. Hetzel U, Sironen T, Laurinmaki P, Liljeroos L, Patjas A, Henttonen H, Vaheri A, Artelt  
648 A, Kipar A, Butcher SJ, Vapalahti O, Hepojoki J. 2013. Isolation, identification, and  
649 characterization of novel arenaviruses, the etiological agents of boid inclusion body  
650 disease. *J Virol* 87:10918–10935.
- 651 8. Stenglein MD, Sanchez-Migallon Guzman D, Garcia VE, Layton ML, Hoon-Hanks LL,  
652 Boback SM, Keel MK, Drazenovich T, Hawkins MG, Derisi JL. 2017. Differential

- 653 Disease Susceptibilities in Experimentally Reptarenavirus-Infected Boa Constrictors and  
654 Ball Pythons. *J Virol* 91.
- 655 9. Abudurexiti A, Adkins S, Alioto D, Alkhovsky SV, Avšič-Županc T, Ballinger MJ,  
656 Bente DA, Beer M, Bergeron É, Blair CD, Briese T, Buchmeier MJ, Burt FJ, Calisher  
657 CH, Cháng C, Charrel RN, Choi IR, Clegg JCS, de la Torre JC, de Lamballerie X, Dèng  
658 F, Di Serio F, Digiaro M, Drebot MA, Duàn X, Ebihara H, Elbeaino T, Ergünay K,  
659 Fulhorst CF, Garrison AR, Gāo GF, Gonzalez JJ, Groschup MH, Günther S, Haenni AL,  
660 Hall RA, Hepojoki J, Hewson R, Hú Z, Hughes HR, Jonson MG, Junglen S, Klempa B,  
661 Klingström J, Kòu C, Laenen L, Lambert AJ, Langevin SA, Liu D, Lukashevich IS, Luò  
662 T, Lǚ C, Maes P, de Souza WM, Marklewitz M, Martelli GP, Matsuno K, Mielke-Ehret  
663 N, Minutolo M, Mirazimi A, Moming A, Mühlbach HP, Naidu R, Navarro B, Nunes  
664 MRT, Palacios G, Papa A, Pauvolid-Corrêa A, Pawęska JT, Qiáo J, Radoshitzky SR,  
665 Resende RO, Romanowski V, Sall AA, Salvato MS, Sasaya T, Shěn S, Shí X, Shirako Y,  
666 Simmonds P, Sironi M, Song JW, Spengler JR, Stenglein MD, Sū Z, Sūn S, Táng S,  
667 Turina M, Wáng B, Wáng C, Wáng H, Wáng J, Wèi T, Whitfield AE, Zerbini FM,  
668 Zhāng J, Zhāng L, Zhāng Y, Zhang YZ, Zhāng Y, Zhou X, Zhū L, Kuhn JH. Taxonomy  
669 of the order Bunyavirales: update 2019. *Arch Virol*. 2019 May 7. doi:10.1007/s00705-  
670 019-04253-6. [Epub ahead of print] PubMed PMID: 31065850.
- 671 10. Hepojoki J, Hepojoki S, Smura T, Szirovicza L, Dervas E, Prahauer B, Nufer L,  
672 Schraner EM, Vapalahti O, Kipar A, Hetzel U. 2018. Characterization of Haartman  
673 Institute snake virus-1 (HISV-1) and HISV-like viruses-The representatives of genus  
674 Hartmanivirus, family Arenaviridae. *PLoS Pathog* 14:e1007415.
- 675 11. Hepojoki J, Salmenpera P, Sironen T, Hetzel U, Korzyukov Y, Kipar A, Vapalahti O.  
676 2015. Arenavirus Coinfections Are Common in Snakes with Boid Inclusion Body  
677 Disease. *J Virol* 89:8657–8660.

- 678 12. Stenglein MD, Jacobson ER, Chang L-W, Sanders C, Hawkins MG, Guzman DS-M,  
679 Drazenovich T, Dunker F, Kamaka EK, Fisher D, Reavill DR, Meola LF, Levens G,  
680 Derisi JL. 2015. Widespread recombination, reassortment, and transmission of  
681 unbalanced compound viral genotypes in natural arenavirus infections. *PLoS Pathog*  
682 11:e1004900.
- 683 13. Chang L-W. 2012. Development of molecular diagnostic tests for Inclusion body disease  
684 in boid snakes. PhD Thesis. University of Florida, Florida.
- 685 14. Korzyukov Y, Hetzel U, Kipar A, Vapalahti O, Hepojoki J. 2016. Generation of Anti-  
686 Boa Immunoglobulin Antibodies for Serodiagnostic Applications, and Their Use to  
687 Detect Anti-Reptarenavirus Antibodies in Boa Constrictor. *PLoS One* 11:e0158417.
- 688 15. Martinez-Sobrido L, Giannakas P, Cubitt B, Garcia-Sastre A, de la Torre, Juan Carlos.  
689 2007. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. *J*  
690 *Virology* 81:12696–12703.
- 691 16. Martinez-Sobrido L, Zuniga EI, Rosario D, Garcia-Sastre A, de la Torre, Juan Carlos.  
692 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic  
693 arenavirus lymphocytic choriomeningitis virus. *J Virol* 80:9192–9199.
- 694 17. Fan L, Briese T, Lipkin WI. 2010. Z proteins of New World arenaviruses bind RIG-I and  
695 interfere with type I interferon induction. *J Virol* 84:1785–1791.
- 696 18. Meyer B, Ly H. 2016. Inhibition of Innate Immune Responses Is Key to Pathogenesis by  
697 Arenaviruses. *J Virol* 90:3810–3818.
- 698 19. Borden KL, Campbell Dwyer EJ, Salvato MS. 1998. An arenavirus RING (zinc-binding)  
699 protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML  
700 nuclear bodies to the cytoplasm. *J Virol* 72:758–766.
- 701 20. Salomoni P, Pandolfi PP. 2002. The role of PML in tumor suppression. *Cell* 108:165–  
702 170.

- 703 21. Zimmerman LM, Vogel LA, Bowden RM. 2010. Understanding the vertebrate immune  
704 system: insights from the reptilian perspective. *J Exp Biol* 213:661–671.
- 705 22. Jaffredo T, Fellah JS, Dunon D. 2006. *Immunology of Birds and Reptiles. Major*  
706 *Reference Works.*
- 707 23. Galabov AS, Velichikova EH. 1975. Interferon production in tortoise peritoneal cells. *J*  
708 *Gen Virol* 28:259–263.
- 709 24. Mondal S, Rai U. 2001. In vitro effect of temperature on phagocytic and cytotoxic  
710 activities of splenic phagocytes of the wall lizard, *Hemidactylus flaviviridis*. *Comp*  
711 *Biochem Physiol A Mol Integr Physiol* 129:391–398.
- 712 25. Mondal S, Rai U. 2002. In vitro effect of sex steroids on cytotoxic activity of splenic  
713 macrophages in wall lizard (*Hemidactylus flaviviridis*). *Gen Comp Endocrinol* 125:264–  
714 271.
- 715 26. Shang S, Zhong H, Wu X, Wei Q, Zhang H, Chen J, Chen Y, Tang X, Zhang H. 2018.  
716 Genomic evidence of gene duplication and adaptive evolution of Toll like receptors  
717 (TLR2 and TLR4) in reptiles. *International Journal of Biological Macromolecules*  
718 109:698–703.
- 719 27. Voogdt CGP, Bouwman LI, Kik MJL, Wagenaar JA, van Putten, Jos P. M. 2016. Reptile  
720 Toll-like receptor 5 unveils adaptive evolution of bacterial flagellin recognition.  
721 *Scientific Reports* 6:19046 EP -.
- 722 28. Zhou Y, Liang Q, Li W, Gu Y, Liao X, Fang W, Li X. 2016. Characterization and  
723 functional analysis of toll-like receptor 4 in Chinese soft-shelled turtle *Pelodiscus*  
724 *sinensis*. *Developmental & Comparative Immunology* 63:128–135.
- 725 29. Merchant M, Williams S, Trosclair PL3, Elsey RM, Mills K. 2007. Febrile response to  
726 infection in the American alligator (*Alligator mississippiensis*). *Comp Biochem Physiol*  
727 *A Mol Integr Physiol* 148:921–925.
- 728 30. Kluger MJ, Ringler DH, Anver MR. 1975. Fever and survival. *Science* 188:166–168.



- 729 31. A Farag M, El Ridi R. 1985. Mixed leucocyte reaction (MLR) in the snake *Psammophis*  
730 *sibilans*. *Immunology* 55.
- 731 32. El Ridi R, Zada S, Afifi A, El Deeb S, El Rouby S, Farag M, Saad A-H. 1988. Cyclic  
732 changes in the differentiation of lymphoid cells in reptiles. *Cell Differentiation* 24:1–8.
- 733 33. Munoz FJ, La Fuente M de. 2001. The effect of the seasonal cycle on the splenic  
734 leukocyte functions in the turtle *Mauremys caspica*. *Physiol Biochem Zool* 74:660–667.
- 735 34. Ansar Ahmed S, Penhale WJ, Talal N. 1985. Sex hormones, immune responses, and  
736 autoimmune diseases. Mechanisms of sex hormone action. *Am J Pathol* 121:531–551.
- 737 35. Klein SL. 2004. Hormonal and immunological mechanisms mediating sex differences in  
738 parasite infection. *Parasite Immunol* 26:247–264.
- 739 36. Saad AH. 1989. Sex-associated differences in the mitogenic responsiveness of snake  
740 blood lymphocytes. *Developmental & Comparative Immunology* 13:225–229.
- 741 37. Gambon-Deza F, Sanchez-Espinel C, Mirete-Bachiller S, Magadan-Mompo S. 2012.  
742 Snakes antibodies. *Developmental & Comparative Immunology* 38:1–9.
- 743 38. Warr GW, Magor KE, Higgins DA. 1995. IgY: clues to the origins of modern antibodies.  
744 *Immunol Today* 16:392–398.
- 745 39. Coe JE, Leong D, Portis JL, Thomas LA. 1976. Immune response in the garter snake  
746 (*Thamnophis ordinoides*). *Immunology* 31:417–424.
- 747 40. Kendall Salanitro S. 1973. Immune Response of Snakes. *Copeia* 1973:504–515.
- 748 41. Chang L, Fu D, Stenglein MD, Hernandez JA, DeRisi JL, Jacobson ER. 2016. Detection  
749 and prevalence of bovid inclusion body disease in collections of boas and pythons using  
750 immunological assays. *Vet J* 218:13–18.
- 751 42. Dervas E, Hepojoki J, Laimbacher A, Romero-Palomo F, Jelinek C, Keller S, Smura T,  
752 Hepojoki S, Kipar A, Hetzel U. 2017. Nidovirus-Associated Proliferative Pneumonia in  
753 the Green Tree Python (*Morelia viridis*). *J Virol*.

- 754 43. Hepojoki J, Kipar A, Korzyukov Y, Bell-Sakyi L, Vapalahti O, Hetzel U, Ross SR. 2015.  
755 Replication of Boid Inclusion Body Disease-Associated Arenaviruses Is Temperature  
756 Sensitive in both Boid and Mammalian Cells. *J Virol* 89:1119.
- 757 44. Cohen J. 1960. A Coefficient of Agreement for Nominal Scales. *Educational and*  
758 *Psychological Measurement* 20:37–46.
- 759 45. Chang L-W, Fu A, Wozniak E, Chow M, Duke DG, Green L, Kelley K, Hernandez JA,  
760 Jacobson ER. 2013. Immunohistochemical detection of a unique protein within cells of  
761 snakes having inclusion body disease, a world-wide disease seen in members of the  
762 families Boidae and Pythonidae. *PLoS One* 8:e82916.
- 763 46. Hepojoki J, Kipar A, Korzyukov Y, Bell-Sakyi L, Vapalahti O, Hetzel U, Ross SR. 2015.  
764 Replication of Boid Inclusion Body Disease-Associated Arenaviruses Is Temperature  
765 Sensitive in both Boid and Mammalian Cells. *J Virol* 89:1119.
- 766 47. Elliott R. Jacobson. 2007. *Infectious Diseases and Pathology of Reptiles: Color Atlas and*  
767 *Text*, 1st ed. CRC Press Inc, Boca Raton.
- 768 48. Ujvari B, Madsen T. 2011. Do natural antibodies compensate for humoral  
769 immunosenescence in tropical pythons? *Functional Ecology* 25:813–817.
- 770 49. Holodick NE, Rodríguez-Zhurbenko N, Hernández AM. 2017. Defining Natural  
771 Antibodies. *Frontiers in immunology* 8:872.
- 772 50. Mims CA. 1981. Vertical transmission of viruses. *Microbiol Rev* 45:267–286.
- 773 51. Hotchin J, Weigand H. 1961. Studies of lymphocytic choriomeningitis in mice. I. The  
774 relationship between age at inoculation and outcome of infection. *J Immunol* 86:392–  
775 400.
- 776 52. Zhou X, Ramachandran S, Mann M, Popkin DL. 2012. Role of lymphocytic  
777 choriomeningitis virus (LCMV) in understanding viral immunology: past, present and  
778 future. *Viruses* 4:2650–2669.

- 779 53. Thomsen AR, Volkert M, Marker O. 1985. Different isotype profiles of virus-specific  
780 antibodies in acute and persistent lymphocytic choriomeningitis virus infection in mice.  
781 *Immunology* 55:213–223.
- 782 54. Aubert RD, Kamphorst AO, Sarkar S, Vezys V, Ha S-J, Barber DL, Ye L, Sharpe AH,  
783 Freeman GJ, Ahmed R. 2011. Antigen-specific CD4 T-cell help rescues exhausted CD8  
784 T cells during chronic viral infection. *Proceedings of the National Academy of Sciences*  
785 *of the United States of America* 108:21182–21187. doi:10.1073/pnas.1118450109.
- 786 55. Oxenius A, Zinkernagel RM, Hengartner H. 1998. Comparison of activation versus  
787 induction of unresponsiveness of virus-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells upon acute  
788 versus persistent viral infection. *Immunity* 9:449–457.
- 789 56. Borrow P, Martinez-Sobrido L, de la Torre, Juan Carlos. 2010. Inhibition of the type I  
790 interferon antiviral response during arenavirus infection. *Viruses* 2:2443–2480.
- 791

792

## FIGURE LEGENDS

793 **Figure 1.** May-Grünwald-Giemsa stained blood smear, BIBD-positive snake (animal no.  
794 1.25). Erythrocytes frequently exhibit intracytoplasmic inclusion bodies (arrows).

795

796 **Figure 2.** Association of BIBD, sex and body weight.

797

798 **Figure 3.** Associations of ELISA test results with age and BIBD status. A) UGV1 IgY, B)  
799 UGV1 IgM, C) UHV1 NP IgY, D) UHV1 NP IgM, E) UHV1 NPC IgY, F) UHV1 NPC IgM.  
800 The red lines indicate the ELISA cut-off point..


801

802 **Figure 4.** Association of body weight and UGV-1 IgY antibodies in female and male snakes.


803

804 **Figure 5.** ELISA results including cut-off values for UGV-1 IgY and IgM, UHV NP IgY and  
805 IgM, UHV NP-C IgY and IgM antibodies in BIBD-positive and BIBD-negative snakes.


806




**Figure 1.** May-Grünwald-Giemsa stained blood smear, BIBD-positive snake (animal no. 1.25). Erythrocytes frequently exhibit intracytoplasmic inclusion bodies (arrows).



**Figure 2.** Association of BIBD, sex and body weight.




**Figure 3 (A to F).** Associations of ELISA test results with age and BIBD status. **A)** UGV1 IgY, **B)** UGV1 IgM, **C)** UHV1 NP IgY, **D)** UHV1 NP IgM, **E)** UHV1 NPC IgY, **F)** UHV1 NPC IgM. The red lines indicate the ELISA cut-off point.



**Figure 4.** Association of body weight and UGV-1 IgY antibodies in female and male snakes.





**Figure 3 (A to F).** Associations of ELISA test results with age and BIBD status. **A)** UGV1 IgY, **B)** UGV1 IgM, **C)** UHV1 NP IgY, **D)** UHV1 NP IgM, **E)** UHV1 NPC IgY, **F)** UHV1 NPC IgM. The red lines indicate the ELISA cut-off point.

**Table 1.** Animals included into the study**A.** Animals with BIBD (diagnosis based on the detection of intracytoplasmic inclusion bodies in blood cells, using blood smears)

Animal (number)	Age (years)	Sex	Weight (kg)	S segment			WB		ELISA					
							UGV-1		UGV-1		UHV NP		UHV NP-C	
				UGV-2	S5-like	TSMV-2	IgY	IgM	IgY	IgM	IgY	IgM	IgY	IgM
1.01	2	M	1.10	+	+	+	-	-	-	+	-	-	-	-
1.02	2	M	2.10	+	+	+	++	++	-	+	-	-	-	-
1.03	3	M	1.40	+	+	+	+	++	-	-	-	-	-	-
1.04	3	M	1.80	+	+	-	++	+	+	+	-	-	-	-
1.05	3	M	3.00	+	+	-	-	+	-	-	+	-	+	-
1.06	3	F	1.00	+	+	-	++	+	-	-	-	-	-	-
1.07	3	F	1.50	+	-	-	+++	+++	+	+	+	+	+	+
1.08	4	M	1.40	+	+	+	+	+	-	+	-	-	-	-
1.09	4	M	1.60	+	+	+	+++	-	-	+	-	-	-	-
1.10	4	M	2.20	+	+	+	++	+++	-	-	-	-	-	-
1.11	4	F	2.50	+	+	-	-	-	-	-	-	-	-	-
1.12	4	F	2.60	+	+	-	-	-	-	-	-	-	-	-
1.13	4	F	3.30	+	+	+	+	+	-	-	-	-	-	-
1.14	4	F	3.40	+	+	-	+	+	-	-	+	+	+	+
1.15	4	F	3.40	+	+	-	+	-	-	+	-	-	-	-
1.16	4	F	3.40	+	+	+	+	+++	-	+	-	-	-	-
1.17	4	F	3.70	+	+	+	-	-	-	-	-	-	-	-
1.18	4	F	3.90	+	+	+	+++	+++	+	+	+	+	+	+
1.19	4	F	4.10	+	+	-	+	+	-	-	-	-	-	-
1.20	5	M	0.90	+	+	+	-	++	-	+	-	+	-	+
1.21	5	M	1.10	+	+	+	-	-	-	+	-	-	-	-
1.22	5	M	1.60	+	+	+	+++	+++	+	+	-	-	+	+
1.23	5	M	2.80	+	-	-	-	++	-	+	-	-	-	-
1.24	5	F	1.70	+	+	+	+	++	-	-	-	-	-	-
1.25	5	F	2.60	+	+	+	-	+	-	-	-	-	-	-
1.26	5	F	4.50	+	+	+	+	++	-	-	-	-	-	-
1.27	6	M	1.80	+	+	+	+	+	-	+	-	-	+	-
1.28	6	M	3.20	+	+	+	-	++	+	+	-	-	-	+
1.29	6	F	2.70	+	+	+	++	-	-	+	-	+	-	+
1.30	6	F	5.50	+	+	+	+++	+++	+	+	-	+	-	+
1.31	7	F	9.00	+	+	+	+	+	+	n.a.	-	-	-	-
1.32	n.a.	M	2.40	+	+	+	+	+	-	+	+	-	-	+
1.33	n.a.	M	2.70	-	+	+	+	-	+	+	+	+	+	+
1.34	n.a.	M	3.10	+	+	+	++	++	+	-	-	-	-	-

n.a. – not available; F – female; M – male; S segment – reptareavirus S segment determined by RT-PCR; WB – Western Blot; Western Blot results graded according to signal intensity: - (negative), + (weakly positive), ++ (moderately positive), +++ (strongly positive); ELISA – Enzyme linked immunosorbent assay

**B. Animals without BIBD (i.e. no evidence of intracytoplasmic inclusion bodies in blood cells, using blood smears)**

Animal (number)	Age (years)	Sex	Weight (kg)	S segment			WB		ELISA					
							UGV-1		UGV-1		UHV NP		UHV NP-C	
				UGV-2	S5-like	TSMV-2	IgY	IgM	IgY	IgM	IgY	IgM	IgY	IgM
2.01	2	M	0.9	-	+	+	++	+	-	+	+	+	+	+
2.02	2	M	1.5	-	+	+	++	+++	-	+	+	-	+	+
2.03	2	F	1.3	-	+	+	-	+	-	-	-	-	+	+
2.04	3	M	1.2	-	+	+	+++	++	+	+	-	-	+	+
2.05	3	M	1.3	+	+	+	-	-	-	+	+	-	+	+
2.06	3	M	1.7	-	+	+	+	+++	-	-	-	-	-	-
2.07	3	M	1.8	-	+	+	-	++	-	+	-	-	+	-
2.08	3	F	2.2	-	+	+	-	-	-	+	-	-	-	-
2.09	4	M	2.1	+	+	+	+++	++	+	-	+	-	-	-
2.10	4	M	2.7	+	+	+	+++	+++	-	+	-	+	-	-
2.11	4	M	3.3	+	+	+	++	++	+	-	+	+	+	+
2.12	4	F	3.7	-	+	+	+++	+++	+	+	+	-	+	+
2.13	4	F	3.8	-	+	+	++	++	+	+	+	+	+	+
2.14	4	F	5.8	-	+	+	+++	++	+	+	-	-	-	-
2.15	4	F	6.8	-	-	-	-	-	-	-	-	-	-	-
2.16	5	M	2.2	+	+	+	-	-	+	-	+	-	+	+
2.17	5	M	2.5	-	+	+	+	+	-	-	+	+	+	+
2.18	5	F	5.0	+	-	+	-	+	+	-	-	-	-	-
2.19	5	F	5.3	-	+	-	++	+	+	+	-	-	-	-
2.20	5	F	5.3	-	-	-	+	-	+	-	-	-	-	-
2.21	5	F	5.5	-	+	+	++	-	+	-	+	-	+	+
2.22	5	F	5.7	-	-	+	++	-	+	+	+	+	+	+
2.23	5	F	6.1	-	+	+	+++	+	+	-	+	-	-	-
2.24	6	M	2.5	+	+	+	-	-	+	-	-	-	-	-
2.25	6	M	3.4	+	+	+	-	-	+	+	-	-	-	-
2.26	6	M	3.5	-	+	+	-	+	-	-	-	-	-	-
2.27	6	F	3.1	-	-	-	+++	+++	+	+	+	+	+	-
2.28	6	F	5.6	-	+	+	+++	+++	+	-	-	-	-	-
2.29	7	M	3.3	+	+	-	-	++	-	-	-	-	-	-
2.30	7	M	4.0	-	+	+	+++	+	+	-	-	-	-	-
2.31	7	F	5.0	+	-	+	+++	+++	+	-	+	-	+	-
2.32	7	F	7.0	-	+	+	+++	+++	+	-	+	+	+	+
2.33	7	F	7.5	-	+	+	++	++	+	+	-	-	-	+
2.34	7	F	10.0	-	+	+	+++	+++	+	-	+	+	+	+
2.35	8	M	3.4	-	+	+	+++	+	+	-	+	+	+	+
2.36	8	F	7.0	-	-	-	+++	++	+	+	-	-	+	+

**Table 2.** Results of inclusion body detection in blood cells (i.e. diagnosis of BIBD) against population parameters. Univariate analysis and stratification by sex.

	Sex (Row%) (Col%)			Weight* (95% CI) N= 70			Age**(n) (95% CI) N=67		
	M	F	All	M	F	All	M	F	All
<b>BIBD -</b>	<b>17</b> (47.22%) (50.00%)	<b>19</b> (52.78%) (52.78 %)	<b>36</b> (100.00%) (51.43%)	<b>2.238</b> (1.788 – 2.801)	<b>4.912</b> (3.919 – 6.156)	<b>3.389</b> (2.767 – 4.149)	<b>4.588</b> (17) (3.643 – 5.534)	<b>5.211</b> (19) (4.464 – 5.957)	<b>4.917</b> (36) (4.343 – 5.491)
<b>BIBD +</b>	<b>17</b> (50.00%) (50.00%)	<b>17</b> (50.00%) (47.22%)	<b>34</b> (100.00%) (48.57%)	<b>1.876</b> (1.532 – 2.297)	<b>3.077</b> (2.373 – 3.991)	<b>2.403</b> (2.010 – 2.873)	<b>4.071</b> (14) (3.305 – 4.838)	<b>4.471</b> (17) (3.922 – 5.019)	<b>4.290</b> (31) (3.854 – 4.726)
<b>All</b>	<b>34</b> (48.57%) (100.00%)	<b>36</b> (51.36%) (100.00%)	<b>70</b> (100.00%) (100.00%)	<b>2.049</b> (1.770 – 2.372)	<b>3.938</b> (3.287 – 4.719)	<b>2.867</b> (2.497 – 3.293)	<b>4.355</b> (31) (3.759 – 4.950)	<b>4.861</b> (36) (4.395 – 5.327)	<b>4.627</b> (67) (4.260 – 4.994)
$\chi^2=0.054, p=0.816$				t=1.2365, df=32 p=0.2253	t=2.8801, df=34 <b>p&lt;0.01</b>	t=2.5748, df=68 <b>p&lt;0.05</b>	t=0.8785, df=29 p=0.3869	t=1.6494, df=34 p=0.1083	t=1.7226, df=65 p=0.0897
*Kg, geometric mean **Years									

**Table 3.** Multiple linear regression: Factors associated with Weight (Kg log10) (n =67)

<b>Factors</b>	<b>Adjusted <i>b</i> (95% CI)</b>	<b><i>P</i>-value</b>
Sex (Female)	0.255 (0.178 – 0.333)	< 0.001
Inclusion detection (positive)	-0.107 (-0.185 – - 0.293)	< 0.01
Age (years)	0.084 (0.058 – 0.110)	< 0.001

Multiple linear regression ( $AdjR^2 = 0.6374$ ).

**Table 4.** Summary of RT-PCR results including test agreement and sensitivity/specificity with inclusion detection considered the gold standard

		BIBD		Total	Cohen's $\kappa$	Sensitivity (95%CI)	Specificity (95%CI)
		+ve	-ve				
UGV-2	+ve	33	10	43	$\kappa=0.688$ (0.524 – 0.852)	97.06% (93.10 – 100)%	72.22% (61.73 – 82.71)%
	-ve	1	26	27			
S5-like	+ve	32	29	61	$\kappa=0.133$ (-0.019 – 0.284)	94.12% (88.61 – 99.63)%	19.44% (10.17 – 28.72)%
	-ve	2	7	9			
TSMV-2	+ve	24	30	54	$\kappa=-0.125$ (-0.320 – 0.069)	70.59 (59.91 – 81.26)%	16.67% (7.94 – 25.40)%
	-ve	10	6	16			
Any segment	+ve	34	32	66	$\kappa=0.108$ (0.005 – 0.212)	100%	11.11% (3.75 – 18.47)%
	-ve	0	4	4			
Total		34	36	70			

**Table 5.** RT-PCR results against population parameters, univariate analysis including stratification by sex

	Sex (Row%) (Col%)			Weight* (95% CI) N= 70			Age**(n) (95% CI) N=67		
	M	F	Total	M	F	Total	M	F	Total
UGV RT-PCR -ve	10 (37.04%) (29.41%)	17 (62.96%) (47.22%)	27 (100.00%) (38.57%)	2.090 (1.466 – 2.981)	4.901 (3.796 – 6.328)	3.575 (2.772 – 4.609)	4.333 (9) (2.615 – 6.052)	5.118 (17) (4.307 – 5.928)	4.846 (26) (4.108 – 5.583)
UGV RT-PCR +ve	24 (55.81%) (70.59%)	19 (44.19%) (52.78%)	43 (100.00%) (61.43%)	2.032 (1.720 – 2.400)	3.238506 2.544208 4.122274	2.497 (2.142 – 2.910)	4.355 (22) (3.759 – 4.969)	4.632 (19) (4.070 – 5.193)	4.488 (41) (4.088 – 4.555)
	$\chi^2=2.341, p=0.126$			t=0.1768, df=32 p=0.8608	t=2.4882, df=34 <b>p&lt;0.05</b>	t=2.622, df=68 <b>p&lt;0.05</b>	t= -0.046, df=29 p=0.9633	t=1.0597, df=34 p=0.2968	t=0.9485, df=65 p=0.346
S5-like RT-PCR -ve	1 (11.11%) (2.94%)	8 (88.89%) (22.22%)	9 (100.00%) (12.86%)	2.800	4.497 (2.937 – 6.884)	4.266 (2.900 – 6.275)	5.000 (1) (4.039 – 6.711)	5.375 (8) (4.039 – 6.711)	5.333 (9) (4.180 – 6.486)
S5-like RT-PCR +ve	33 (54.10%) (97.06%)	28 (45.90%) (77.78%)	61 (100.00%) (87.14%)	2.030 (1.748 – 2.357)	3.792 (3.070 – 4.684)	2.704 (2.336 – 3.130)	4.333 (30) (3.718 – 4.948)	4.714 (28) (4.210 – 5.219)	4.517 (58) (4.126 – 4.909)
	$\chi^2=5.8019, p<0.05$			t=..., df=32 p=...	t=0.791, df=34 p=0.4344	t=2.264, df=68 <b>p&lt;0.05</b>	t=..., df=29 p=....	t=1.2051, df=34 p=0.2365	t=1.528, df=65 p=0.131
TSMV-2 RT-PCR -ve	4 (25.00%) (11.76%)	12 (75.00%) (33.33%)	16 (100.00%) (22.86%)	2.658 (1.734 – 4.074)	3.338 (2.301 – 4.842)	3.153 (2.383 – 4.172)	4.500 (4) (1.453 – 7.547)	4.500 (12) (3.622 – 5.378)	4.5 (16) (3.722 – 5.278)
TSMV-2 RT-PCR +ve	30 (55.56%) (88.24%)	24 (44.44%) (66.67%)	54 (100.00%) (77.14%)	1.979 (1.688 – 2.321)	4.278 (3.464 – 5.283)	2.788 (2.368 – 3.282)	4.333 (27) (3.694 – 4.973)	5.042 (24) (4.395 – 5.619)	4.667 (51) (4.236 – 5.098)
	$\chi^2=4.6133, p<0.05$			t=1.3371, df=32 p=0.1906	t=-1.3264, df=34 p=0.1936	t=0.743, df=68 p=0.460	t=1.1885, df=29 P=0.8518	t=-1.1170, df=34 p=0.2718	t=-0.384, df=65 p=0.702
<b>Total</b>	34 (48.57%) (100.00%)	36 (51.43%) (100.00%)	70 (100.00%) (100.00%)	2.049 (1.770 – 2.372)	3.938 (3.287 – 719)	2.867 (2.497 – 3.293)	4.355 (31) (3.759 – 4.950)	4.861 (36) (4.395 – 5.329)	4.626 (67) (4.260 – 4.994)
*Kg, geometric mean **Mean Years									

S4	Sex		Total
	Male	Female	
negative	10	17	27
	37.04	62.96	100.00
	29.41	47.22	38.57
positive	24	19	43
	55.81	44.19	100.00
	70.59	52.78	61.43
Total	34	36	70
	48.57	51.43	100.00
	100.00	100.00	100.00

Pearson chi2(1) = 2.3410 Pr = 0.126

Fisher's exact = 0.147

1-sided Fisher's exact = 0.099



**Table 6.** Results of the detection of IgY and IgM plasma antibodies against UGV-1 virions using WB in comparison to the diseases status (BIBD-positive or – negative, based on the presence of cytoplasmic IB in blood cells

Western blotting		BIBD			Cohen's $\kappa$	Sensitivity (95%CI)	Specificity (95%CI)
		+ve	-ve	Total			
WB UGV1 IgY	+ve	24	25	49	$\kappa = 0.011$ (-0.195 – 0.218)	70.59% (59.91 – 81.26)%	30.56% (19.76 – 41.35)%
	-ve	10	11	21			
WB UGV1 IgM	+ve	25	27	52	$\kappa = -0.015$ (-0.222 – 0.193)	73.53% (63.19 – 83.86)%	25.00% (14.86 – 35.14)%
	-ve	9	9	18			
Total		34	36	70			

**Table 7.** ELISA results against RT-PCR and IB detection

Alternative test \ ELISA	UGV1 IgY* (n) (95%CI)	UGV1 IgM* GM (n) (95%CI)	UHV1 NP IgY* (n) (95%CI)	UHV1 NP IgM* (n) (95%CI)	UHV-1 NP-C IgY* (n) (95%CI)	UHV-1 NP-C IgM* (n) (95%CI)
<b>BIBD +ve</b>	<b>0.155</b> (33) (0.095 – 0.252)	<b>0.561</b> (33) (0.479 – 0.657)	<b>0.156</b> (34) (0.114 – 0.213)	<b>0.250</b> (34) (0.202 – 0.308)	<b>0.251</b> (34) (0.191 – 0.329)	<b>0.290</b> (34) (0.241 – 0.351)
<b>BIBD -ve</b>	<b>0.553</b> (36) (0.337 – 0.906)	<b>0.448</b> (36) (0.399 – 0.503)	<b>0.306</b> (36) (0.244 – 0.385)	<b>0.255</b> (36) (0.199 – 0.327)	<b>0.556</b> (36) (0.452 – 0.682)	<b>0.379</b> (36) (0.339 – 0.422)
t-test	t = 3.7246, df=67 <b>p&lt;0.001</b>	t = -2.3586, df=67 <b>p&lt;0.05</b>	t = 3.5899, df=68 <b>p&lt;0.001</b>	t = 0.1294, df=68 p=0.903	t = 4.771, df=68 <b>p&lt;0.001</b>	t = 2.5368, df=68 <b>p&lt;0.05</b>
<b>UGV-2 RT-PCR +ve</b>	<b>0.209</b> (42) (0.133 – 0.329)	<b>0.464</b> (42) (0.398 – 0.540)	<b>0.173</b> (43) (0.132 – 0.226)	<b>0.254</b> (43) (0.214 – 0.301)	<b>0.282</b> (43) (0.221 – 0.361)	<b>0.296</b> (43) (0.254 – 0.344)
<b>UGV-2 PR-PCR -ve</b>	<b>0.530</b> (27) (0.288 – 0.975)	<b>0.464</b> (27) (0.458 – 0.596)	<b>0.326</b> (27) (0.251 – 0.123)	<b>0.249</b> (27) (0.179 – 0.346)	<b>0.598</b> (27) (0.480 – 0.744)	<b>0.402</b> (27) (0.356 – 0.454)
t-test	t = 2.5322, df=67 <b>p&lt;0.05</b>	t = -1.181, df=67 p=0.2118	t = 3.2325, df=68 <b>p&lt;0.01</b>	t = -0.1199, df=68 p=0.9049	t = 4.2732, df=68 <b>p&lt;0.001</b>	t = 2.9145, df=68 <b>p&lt;0.01</b>
<b>S5-like RT-PCR +ve</b>	<b>0.262</b> (60) (0.180 – 0.382)	<b>0.495</b> (60) (0.445 – 0.551)	<b>0.207</b> (61) (0.168 – 0.256)	<b>0.251</b> (61) (0.210 – 0.301)	<b>0.353</b> (61) (0.292 – 0.427)	<b>0.333</b> (61) (0.295 – 0.375)
<b>S5-like PT-PCR -ve</b>	<b>0.745</b> (9) (0.171 – 0.324)	<b>0.522</b> (9) (0.378 – 0.718)	<b>0.339</b> (9) (0.156 – 0.733)	<b>0.260</b> (9) (0.197 – 0.344)	<b>0.592</b> (9) (0.263 – 1.330)	<b>0.335</b> (9) (0.295 – 0.375)
t-test	t = 1.9239, df=67 p=0.0586	t = 0.3602, df=67 p=0.7199	t = 1.6353, df=68 p=0.1068	t = 0.1522, df=68 p=0.8795	t = 1.8398, df=68 p=0.0702	t = 0.041, df=68 p=0.9674
<b>SMTV-2 RT-PCR +ve</b>	<b>0.334</b> (53) (0.220 – 0.508)	<b>0.506</b> (53) (0.452 – 0.567)	<b>0.235</b> (54) (0.192 – 0.289)	<b>0.259</b> (54) (0.213 – 0.315)	<b>0.407</b> (54) (0.334 – 0.495)	<b>0.359</b> (54) (0.320 – 0.402)
<b>SMTV-2 PT-PCR -ve</b>	<b>0.212</b> (16) (0.088 – 0.507)	<b>0.475</b> (16) (0.383 – 0.589)	<b>0.178</b> (16) (0.098 – 0.546)	<b>0.230</b> (16) (0.179 – 0.296)	<b>0.292</b> (16) (0.171 – 0.500)	<b>0.258</b> (16) (0.198 – 0.337)
t-test	t = -1.0373, df=67 p=0.3033	t = -0.5349, df=67 p=0.5945	t = -1.1503, df=68 p=0.2541	t = -0.6136, df=68 p=0.5415	t = -1.4677, df=68 p=0.1468	t = -2.6477, df=68 <b>p&lt;0.05</b>
Total	0.301 (69) (0.207 – 0.436)	0.499 (69) (0.452 – 0.550)	0.221 (70) (0.180 – 0.270)	0.252 (70) (0.215 – 0.296)	0.377 (70) (0.312 – 0.456)	0.333 (70) (0.299 – 0.371)

\*Optical density geometric mean

**Table 8.** Associations between ELISA results and population parameters, univariate analysis

OD geometric mean	Sex (95%CI)				Weight Linear regression results				Age ANOVA results	
	Male	Female	All	p value	F R <sup>2</sup>	Coef	Adjusted <i>b</i> (95%CI)	p value	F	p value
UGV-1 RT-PCR IgY	<b>0.208</b> (0.122 – 0.352)	<b>0.422</b> (0.251 – 0.710)	<b>0.301</b> (0.207 – 0.436)	t = -1.9407, df=67 p=0.0565	(1.67) =32.4 0.316	-0.245 (-1.532 - 0.959)	1.556 (1.010 – 2.102)	p<0.0001	(6,59) =3.52	p<0.01
UGV1 RT-PCR IgM	<b>0.540</b> (0.472 – 0.618)	<b>0.462</b> (0.400 – 0.534)	<b>0.499</b> (0.452 – 0.550)	t = 1.6002, df=67 p=0.1143	(1.67) =4.90 0.0542	-0.217 (-0.304 - -0.131)	-0.188 (-0.357 – -0.185)	P<0.05	(6.59) =1.26	p=0.2876
UHV-1 NP RT-PCR IgY	<b>0.242</b> (0.196 – 0.299)	<b>0.202</b> (0.142 – 0.287)	<b>0.221</b> (0.180 – 0.270)	t = 0.8919, df=68 p=0.3756	(1.68) =0.04 -0.141	-0.673 (-0.858 - 0.487)	0.036 (-0.319 – 0.391)	p=0.84	(6,60) =1	p=0.4365
UHV-1 NP RT-PCR IgM	<b>0.265</b> (0.228 – 0.308)	<b>0.241</b> (0.181 – 0.320)	<b>0.252</b> (0.215 – 0.296)	t = 0.5993, df=68 p=0.5510	(1,68) =0.43 -0.0083	-0.556 (-0.701 - -0.411)	-0.092 (-0.369 – 0.186)	p=0.513	(6,60) =0.71	p=0.6398
UHV-1 NPC RT-PCR IgY	<b>0.382</b> (0.298 – 0.489)	<b>0.373</b> (0.276 – 0.504)	<b>0.377</b> (0.312 – 0.456)	t = 1.1234, df=68 p=0.9021	(1,68) =0.86 -0.0021	-0.494 (-0.666 – -0.321)	0.153 (-0.178 – 0.485)	p=0.358	(6,60) =1.45	p=0.2093
UHV-1 NP-C RT-PCR IgM	<b>0.335</b> (0.294 – 0.381)	<b>0.331</b> (0.277 – 0.396)	<b>0.333</b> (0.299 – 0.371)	t = 0.1052, df=68 p=0.9165	(1,68) =0.71 -0.0041	-0.514 (-0.312 – -0.416)	0.080 (-0.108 – 0.268)	p=0.401	(6,60) =0.77	p=0.598

**Table 9.** Results obtained from the examination of UGV-2, S5-like and TSMV-2 specific S-segments by RT-PCR and UGV-1, UHV-1 NP and UHV-1 NP-C specific IgY and IgM antibodies by ELISA

RT-PCR	UGV-1			UHV-1 NP			UHV-1 NP-C		
	IgY	IgM n=33 tested	IgY and IgM n=33 tested	IgY	IgM	IgY and IgM	IgY	IgM	IgY and IgM
Positive 34/34 (100%)	Pos 9/34 (26.47%)	Pos 19/33 (57.58%)	Pos 7/33 (21.21%)	Pos 6/34 (17.65%)	Pos 7/34 (20.59%)	Pos 4/34 (11.76%)	Pos 7/34 (20.59%)	Pos 10/34 (29.41%)	Pos 5/34 (14.71%)
	Neg 25/34 (73.53%)	Neg 14/33 (42.42%)	Neg 13/33 (39.39%)	Neg 28/34 (82.35%)	Neg 27/34 (79.41%)	Neg 25/34 (73.53%)	Neg 27/34 (79.41%)	Neg 24/34 (70.59%)	Neg 22/34 (64.71%)
3 Segments 23/34 (67.65%)	Pos 6/23 (26.09%)	Pos 14/22 (63.64%)	Pos 4/22 (18.18%)	Pos 2/23 (8.7%)	Pos 4/23 (17.39%)	Pos 1/23 (4.35%)	Pos 3/23 (13.04%)	Pos 7/23 (30.43%)	Pos 2/23 (8.7%)
	Neg 17/23 (73.91%)	Neg 8/22 (36.36%)	Neg 7/22 (31.82%)	Neg 21/23 (91.3%)	Neg 19/23 (82.61%)	Neg 18/23 (78.26%)	Neg 20/23 (86.96%)	Neg 16/23 (69.57%)	Neg 15/23 (65.22%)
2 Segments 9/34 (26.47%)	Pos 2/9 (22.22%)	Pos 3/9 (33.33%)	Pos 2/9 (22.22%)	Pos 3/9 (33.33%)	Pos 2/9 (22.22%)	Pos 2/9 (22.22%)	Pos 3/9 (33.33%)	Pos 2/9 (22.22%)	Pos 2/9 (22.22%)
	Neg 7/9 (77.78%)	Neg 6/9 (66.67%)	Neg 6/9 (66.67%)	Neg 6/9 (66.67%)	Neg 7/9 (77.78%)	Neg 6/9 (66.67%)	Neg 6/9 (66.67%)	Neg 7/9 (77.78%)	Neg 6/9 (66.67%)
1 Segment 2/34 (5.88%)	Pos 1/2 (50%)	Pos 2/2 (100%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)
	Neg 1/2 (50%)	Neg 0/2 (0%)	Neg 0/2 (0%)	Neg 1/2 (50%)	Neg 1/2 (50%)	Neg 1/2 (50%)	Neg 1/2 (50%)	Neg 1/2 (50%)	Neg 1/2 (50%)

**A. Animals with BIBD**

Pos – positive; Neg - negative

RT-PCR	UGV-1			UHV-1 NP			UHV-1 NP-C		
	IgY	IgM	IgY and IgM	IgY	IgM	IgY and IgM	IgY	IgM	IgY and IgM
Positive/ Negative 36/36 (100%)	Pos 24/36 (66.67%)	Pos 16/36 (44.44%)	Pos 10/36 (27.78%)	Pos 17/36 (47.22%)	Pos 9/36 (25%)	Pos 8/36 (22.22%)	Pos 19/36 (52.78%)	Pos 17/36 (47.22%)	Pos 16/36 (44.44%)
	Neg 12/36 (33.33%)	Neg 20/36 (55.56%)	Neg 6/36 (16.67%)	Neg 19/36 (52.78%)	Neg 27/36 (75%)	Neg 18/36 (50%)	Neg 17/36 (47.22%)	Neg 19/36 (52.78%)	Neg 16/36 (44.44%)
Positive 32/36 (88.89%)	Pos 21/32 (65.63%)	Pos 14/32 (43.75%)	Pos 8/32 (25.00%)	Pos 16/32 (50%)	Pos 9/32 (28.13%)	Pos 8/32 (25.00%)	Pos 17/32 (53.13%)	Pos 16/32 (50%)	Pos 15/32 (46.88%)
	Neg 11/32 (34.38%)	Neg 18/32 (56.25%)	Neg 5/32 (15.63%)	Neg 16/32 (50%)	Neg 23/32 (71.88%)	Neg 15/32 (46.88%)	Neg 15/32 (46.88%)	Neg 16/32 (50%)	Neg 14/32 (43.75%)
3 Segments 7/32 (21.88%)	Pos 5/7 (71.43%)	Pos 3/7 (42.86%)	Pos 1/7 (14.29%)	Pos 4/7 (57.14%)	Pos 2/7 (28.57%)	Pos 1/7 (14.29%)	Pos 3/7 (42.86%)	Pos 3/7 (42.86%)	Pos 3/7 (42.86%)
	Neg 2/7 (28.57%)	Neg 4/7 (57.14%)	Neg 0/7 (0%)	Neg 3/7 (42.86%)	Neg 5/7 (71.43%)	Neg 2/7 (28.57%)	Neg 4/7 (57.14%)	Neg 4/7 (57.14%)	Neg 4/7 (57.14%)
2 Segments 23/32 (71.88%)	Pos 14/23 (60.87%)	Pos 9/23 (39.13%)	Pos 5/23 (21.74%)	Pos 11/23 (47.83%)	Pos 6/23 (26.09%)	Pos 6/23 (26.09%)	Pos 13/23 (56.52%)	Pos 12/23 (52.17%)	Pos 11/23 (47.83%)
	Neg 9/23 (39.13%)	Neg 14/23 (60.87%)	Neg 5/23 (21.74%)	Neg 12/23 (52.17%)	Neg 17/23 (73.91%)	Neg 12/23 (52.17%)	Neg 10/23 (43.48%)	Neg 11/23 (47.83%)	Neg 9/23 (39.13%)
1 Segment 2/32 (6.25%)	Pos 2/2 (100%)	Pos 2/2 (100%)	Pos 2/2 (100%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)	Pos 1/2 (50%)
	Neg 0/2 (0%)	Neg 0/2 (0%)	Neg 0/2 (0%)	Neg 1/2 (50%)	Neg 1/2 (50%)	Neg 1/2 (50%)	Neg 1/2 (50%)	Neg 1/2 (50%)	Neg 1/2 (50%)
Negative 4/36 (11.11%)	Pos 3/4 (75%)	Pos 2/4 (50%)	Pos 2/4 (50%)	Pos 1/4 (25%)	Pos 0/4 (0%)	Pos 0/4 (0%)	Pos 2/4 (50%)	Pos 1/4 (25%)	Pos 1/4 (25%)
	Neg 1/4 (25%)	Neg 2/4 (50%)	Neg 1/4 (25%)	Neg 3/4 (75%)	Neg 4/4 (100%)	Neg 3/4 (75%)	Neg 2/4 (50%)	Neg 3/4 (75%)	Neg 2/4 (50%)

**B. Animals without BIBD**

**Table 10.** ELISA results based on the cut-off points against inclusion detection including test agreement and sensitivity/Specificity

ELISA test	BIBD			Cohen's $\kappa$ (95%CI)	Sensitivity	Specificity
	+ve	-ve	Total			
UGV1 IgY	+ve	25	11	$\kappa = 0.429$ (0.213 – 0.645)	73.53% (63.19 – 83.86) %	69.44% (58.65 – 80.24) %
	-ve	9	25			
UGV1 IgM*	+ve	14	20	$\kappa = -0.131$ (-0.360 – 0.097)	42.42% (30.76 – 54.09) %	44.44% (32.72 – 56.17) %
	-ve	19	16			
UHV1 NP IgY	+ve	28	19	$\kappa = 0.293$ (0.075 – 0.510)	82.35% (73.42 – 91.28) %	47.22% (35.53 – 58.92) %
	-ve	6	17			
UHV1 NP IgM	+ve	7	9	$\kappa = 0.043$ (-0.145 – 0.232)	79.41% (69.94 – 88.88) %	25.00% (14.86 – 35.14) %
	-ve	24	27			
UHV1 NP-C IgY	+ve	27	17	$\kappa = 0.319$ (0.100 – 0.539)	79.41% (69.94 – 88.88) %	52.78% (41.08 – 64.47) %
	-ve	7	19			
UHV1 NP-C IgM	+ve	24	19	$\kappa = 0.177$ (-0.051 – 0.405)	70.59% (59.91 – 81.26) %	47.22% (35.53 – 58.92) %
	-ve	10	17			
Total		34	36	70		
<i>*missing value</i>						

**Table 11.** Agreements of ELISA tests with IB detection and RT-PCR

ELISA test		BIBD			UGV-2			S5-like			SMTV-2			Total
		+ve	-ve	Cohen's $\kappa$	+ve	-ve	Cohen's $\kappa$ (95%CI)	+ve	-ve	Cohen's $\kappa$	+ve	-ve	Cohen's $\kappa$	
UGV1 IgY	+ve	25	11	$\kappa = 0.429$ (0.213 – 0.645)	28	8	0.339 (0.119 – 0.558)	34	2	0.153 (-0.009 – 0.316)	26	10	-0.103 (-0.307 – 0.102)	36
	-ve	9	25		15	19		27	7		28	6		34
UGV1 IgM*	+ve	14	20	$\kappa = -0.131$ (-0.360 – 0.097)	21	13	0.018 (-0.209 – 0.244)	30	4	0.025 (-0.134 – 0.184)	25	9	-0.064 (-0.267 – 0.139)	34
	-ve	19	16		21	14		30	5		28	7		35
UHV1 NP IgY	+ve	28	19	$\kappa = 0.293$ (0.075 – 0.510)	33	14	0.256 (0.018 – 0.494)	42	5	0.080 (-0.129 – 0.0289)	35	12	-0.088 (-0.307 – 0.131)	47
	-ve	6	17		10	13		19	4		19	4		23
UHV1 NP IgM	+ve	27	27	$\kappa = 0.043$ (-0.145 – 0.232)	35	19	0.119 (-0.103 – 0.342)	47	7	-0.005 (-0.220 – 0.209)	40	14	-0.134 (-0.333 – 0.064)	54
	-ve	7	9		8	8		14	2		14	2		16
UHV1 NP-C IgY	+ve	27	17	$\kappa = 0.319$ (0.100 – 0.539)	33	11	0.363 (0.133 – 0.592)	40	4	0.117 (-0.083 – 0.318)	33	11	-0.063 (-0.284 – 0.159)	44
	-ve	7	19		10	16		21	5		21	5		26
UHV1 NP-C IgM	+ve	24	19	$\kappa = 0.177$ (-0.051 – 0.405)	31	12	0.276 (0.037 – 0.515)	37	6	-0.032 (-0.209 – 0.144)	30	13	-0.207 (-0.400 – -0.014)	43
	-ve	10	17		12	15		24	3		24	3		27
Total		34	36		43	27		61	9		54	16		70

\*missing value

**Table 12A.** IgY ELISA cut-off point results against population parameters, univariate analysis including stratification by sex

	Sex (Row%) (Col%)			Weight* (95% CI) N= 70			Age**(n) (95% CI) N=67		
	M	F	Total	M	F	Total	M	F	Total
UGV- 1 IgY ELISA -ve	20 (55.56%) (58.82%)	16 (44.44%) (44.44%)	36 (100.00%) (51.43%)	1.809 (1.484 – 2.206)	2.788 (2.167 – 3.588)	2.193 (1.858 – 2.589)	3.947 (19) (3.220 – 4.674)	4.063 (16) (3.568 – 4.557)	4.000 (35) (3.567 – 4.329)
UGV-1 IgY ELISA +ve	14 (41.18%) (41.18%)	20 (58.82%) (55.86%)	34 (100.00%) (48.57%)	2.448 (1.995 – 3.004)	5.192 (4.283 – 6.293)	3.809 (3.159 – 4.594)	5.000 (12) (3.951 – 6.049)	5.500 (20) (4.865 – 6.135)	5.313 (32) (4.783 – 5.842)
	$\chi^2 = 1.4473, p=0.229$			t = -2.1855, df=32 p<0.05	t = -4.2166, df=34 p<0.001	t = -4.480, df=68 p<0.0001	t = -1.8251, df=29 p=0.0783	t = -3.609, df=34 p<0.005	t = -3.935, df=65 p<0.001
UHV-1 NP IgY ELISA -ve	23 (48.94%) (67.65%)	24 (51.06%) (66.67%)	47 (100.00%) (67.14%)	2.005 (1.666 – 2.412)	3.711 (2.930 – 4.701)	2.745 (2.313 – 3.259)	4.500 (22) (3.819 – 5.181)	4.750 (24) (4.163 – 5.337)	4.630 (46) (3.865 – 5.373)
UHV-1 NP IgY ELISA +ve	11 (47.83%) (32.35%)	12 (52.17%) (33.33%)	23 (100.00%) (32.86%)	2.145 (1.622 – 2.837)	4.436 (3.268 – 6.020)	3.134 (2.442 – 4.020)	4.000 (9) (2.562 – 5.438)	5.083 (12) (4.207 – 5.959)	4.619 (21) (3.865 – 5.374)
	$\chi^2 = 0.076, p=0.930$			t = -0.4349, df=32 p=0.6667	t = -0.9422, df=34 p=0.3527	t = -0.894, df=68 p=0.3746	t = 0.773, df=29 p=0.4458	t = -0.6797, df=34 p=0.5013	t = 0.285, df=65 p=9774
UHV-1 NP-C IgY ELISA -ve	21 (47.73%) (61.76%)	23 (52.27%) (63.89%)	44 (100.00%) (62.86%)	2.121 (1.745 – 2.576)	3.861 (3.086 – 4.831)	2.901 (2.446 – 3.440)	4.526 (19) (3.784 – 5.269)	4.739 (23) (4.265 – 5.213)	4.643 (42) (4.237 – 5.049)
UHV-1 NP-C IgY ELISA +ve	13 (50.00%) (38.24%)	13 (50.00%) (36.11%)	26 (100.00%) (37.14%)	1.938 (1.508 – 2.492)	4.079 (2.870 – 5.798)	2.812 (2.186 – 3.618)	4.083 (12) (2.951 – 5.215)	5.077 (13) (3.989 – 6.165)	4.600 (25) (3.846 – 5.354)
	$\chi^2 = 0.0338, p=0.854$			t = 0.6009, df=32 p=0.5521	t = -0.2922, df=34 p=0.7718	t = 0.2146, df=68 p=0.831	t = 0.7342, df=29 p=0.4687	t = -0.7021, df=34 p=0.4874	t = 0.112, df=35 p=0.914
<b>Total</b>	34 (48.57%) (100.00%)	36 (51.43%) (100.00%)	70 (100.00%) (100.00%)	2.049 (1.770 – 2.372)	3.938 (3.287 – 4.719)	2.867 (2.497 – 3.293)	4.355 (31) (3.759 – 4.950)	4.861 (36) (4.395 – 5.327)	4.626 (67) (4.260 – 4.994)
*Kg, geometric mean , **Mean Years									



**Table 12B.** IgM ELISA cut-off point results against population parameters, univariate analysis including stratification by sex

	Sex (Row%) (Col%)			Weight* (95% CI) UGV-1: N= 69; UHV- NP, UHV-1 NP-C: N=70			Age**(n) (95% CI) UGV-1: N=66; UHV-1 NP, UHV-1 NP-C: N=67		
	M	F	Total	M	F	Total	M	F	Total
UGV- 1 IgM ELISA -ve	<b>14</b> (41.18%) (41.18%)	<b>20</b> (58.82%) (57.14%)	<b>34</b> (100.00%) (49.28%)	<b>2.623</b> (2.204 – 3.120)	<b>3.771</b> (2.867 – 4.962)	<b>3.248</b> (2.712 – 3.889)	<b>5.000</b> (13) (3.983 – 6.017)	<b>4.750</b> (20) (4.145 – 5.355)	<b>4.848</b> (33) (4.338 – 5.359)
UGV-1 IgM ELISA +ve	<b>20</b> (57.14%) (58.82%)	<b>15</b> (42.86%) (42.86%)	<b>35</b> (100.00%) (50.72%)	<b>1.724</b> (1.424 – 2.087)	<b>3.949</b> (3.089 – 5.048)	<b>2.459</b> (2.008 – 3.011)	<b>3.889</b> (18) (3.167 – 4.610)	<b>4.867</b> (15) (4.060 – 5.674)	<b>4.333</b> (33) 3.797 – 4.870)
<b>Total</b>	<b>34</b> (49.28%) 100.00%)	<b>35</b> (50.72%) (100.00%)	<b>69</b> (100.00%) (100.00%)	<b>2.049</b> (1.770 – 2.372)	<b>3.938</b> (3.287 – 4.719)	<b>2.820</b> (2.461 – 3.233)	<b>4.355</b> (31) (3.759 – 4.950)	<b>4.800</b> (35) (4.338 – 5.262)	<b>4.595</b> (66) (4.225 – 5.957)
	$\chi^2 = 1.7590, p=0.185$			t = 3.2678, df=32 <b>p&lt;0.01</b>	t = -0.2540, df=33 p=0.818	t = 2.0827, df=67 <b>p&lt;0.05</b>	t = 1.968, df=29 p=0.0578	t = -0.2502, df=33 p=0.8040	t = 1.417, df=67 p=0.161
UHV-1 NP IgM ELISA -ve	<b>27</b> (50.00%) (79.41%)	<b>27</b> (50.00%) (75.00%)	<b>54</b> (100.00%) (77.14%)	<b>2.042</b> (1.757 – 2.374)	<b>3.841</b> (3.109 – 4.746)	<b>2.801</b> (2.404 – 3.263)	<b>4.280</b> (25) (3.633 – 4.927)	<b>4.778</b> (27) (4.237 – 5.319)	<b>4.538</b> (52) (4.128 – 4.949)
UHV-1 NP IgM ELISA +ve	<b>7</b> (43.75%) (20.59%)	<b>9</b> (56.25%) (25.00%)	<b>16</b> (100.00%) (22.86%)	<b>2.075</b> (1.212 – 3.553)	<b>4.245</b> (2.764 – 6.521)	<b>3.104</b> (2.183 – 4.413)	<b>4.667</b> (6) (2.603 – 6.730)	<b>5.111</b> (9) (3.994 – 6.228)	<b>4.629</b> (15) (4.034 (4.260 – 4.994)
	$\chi^2 = 0.1930, p=0.660$			t = -0.0881, df=32 p=0.9304	t = -0.4807, df=34 p=0.6338	t = -0.6185, df=68 p=0.538	t = -0.5174, df=29 p=0.6088	t = -0.6237, df=34 p=0.5370	t = -0.893, df=65 p=0.375
UHV-1 NP-C IgM ELISA -ve	<b>21</b> (48.84%) (61.76%)	<b>22</b> (51.16%) (61.11%)	<b>43</b> (100.00%) (61.43%)	<b>2.155</b> (1.812 – 2.564)	<b>3.754</b> (3.003 – 4.602)	<b>2.863</b> (2.436 – 3.364)	<b>4.350</b> (20) (3.617 – 5.083)	<b>4.682</b> (22) (4.200 – 5.163)	<b>4.524</b> (42) (4.109 – 4.938)
UHV-1 NP-C IgM ELISA +ve	<b>13</b> (48.15%) (38.24%)	<b>14</b> (51.85%) (38.89%)	<b>27</b> (100.00%) (38.57%)	<b>1.888</b> (1.414 – 2.521)	<b>4.247</b> (3.018 – 5.978)	<b>2.875</b> (2.204 – 3.750)	<b>4.364</b> (11) (3.152 – 5.576)	<b>5.143</b> (14) (4.134 – 6.152)	<b>4.800</b> (25) (4.065 – 4.994)
	$\chi^2 = 0.0032, p=0.955$			t = 0.8911, df=32 p=0.3795	t = -0.6709, df=34 p=0.5068	t = -0.295, df=68 p=0.797	t = -0.022, df=29 p=0.9826	t = -0.9792, df=34 p=0.3344	t = -0.723, df=65 p=0.472
<b>Total</b>	<b>34</b> (48.57%) (100.00%)	<b>36</b> (51.43%) (100.00%)	<b>70</b> (100.00%) (100.00%)	<b>2.049</b> (1.770 – 2.372)	<b>3.938</b> (3.287 – 4.719)	<b>2.867</b> (2.497 – 3.293)	<b>4.355</b> (31) (3.759 – 4.950)	<b>4.861</b> (36) (4.395 – 5.327)	<b>4.626</b> (67) (4.260 – 4.994)

\*Kg, geometric mean , \*\*Mean Years